Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023


OR


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from ____ to _____

Commission File Number: 001-32433

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Its Charter)


Delaware						20-1297589
(State or Other Jurisdiction of Incorporation or Organization)						(I.R.S. Employer Identification No.)

660 White Plains Road

Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800


(Registrant's Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	PBH	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☒

Accelerated Filer

☐

Non-Accelerated Filer

☐

Smaller Reporting Company

☐

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of February 2, 2024, there were 49,649,288 shares of common stock outstanding.

Prestige Consumer Healthcare Inc.

Form 10-Q

Index


PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements
	Condensed Consolidated Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2023 and 2022 (unaudited)	2
	Condensed Consolidated Balance Sheets as of December 31, 2023 and March 31, 2023 (unaudited)	3
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended December 31, 2023 and 2022 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the three and nine months ended December 31, 2023 and 2022 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33

Item 4.	Controls and Procedures	33

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors	33

Item 6.	Exhibits	35

	Signatures	36

TRADEMARKS AND TRADE NAMES

Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks and trade names when they appear in this Quarterly Report on Form 10-Q.

-1-

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2023		2022		2023		2022
Revenues
Net sales	$	282,715	$	275,495	$	848,321	$	841,783
Other revenues	26		29		45		73
Total revenues	282,741		275,524		848,366		841,856

Cost of Sales
Cost of sales excluding depreciation	122,794		123,251		369,772		364,631
Cost of sales depreciation	2,009		1,871		5,963		5,695
Cost of sales	124,803		125,122		375,735		370,326
Gross profit	157,938		150,402		472,631		471,530

Operating Expenses
Advertising and marketing	39,466		30,423		115,799		114,193
General and administrative	26,003		26,536		79,687		79,688
Depreciation and amortization	5,637		6,259		16,869		19,067


Total operating expenses	71,106		63,218		212,355		212,948
Operating income	86,832		87,184		260,276		258,582

Other expense


Interest expense, net	16,575		17,917		51,900		50,188

Other expense (income), net	682		1,150		(327)		2,787
Total other expense, net	17,257		19,067		51,573		52,975
Income before income taxes	69,575		68,117		208,703		205,607
Provision for income taxes	16,529		16,166		48,822		47,361




Net income	$	53,046	$	51,951	$	159,881	$	158,246

Earnings per share:
Basic	$	1.07	$	1.05	$	3.21	$	3.17
Diluted	$	1.06	$	1.04	$	3.19	$	3.14

Weighted average shares outstanding:
Basic	49,740		49,693		49,731		49,919
Diluted	50,125		50,186		50,134		50,392

Comprehensive income, net of tax:
Currency translation adjustments	7,465		6,970		3,035		(9,667)

Net loss on termination of pension plan	—		—		—		(790)

Total other comprehensive income (loss)	7,465		6,970		3,035		(10,457)
Comprehensive income	$	60,511	$	58,921	$	162,916	$	147,789

See accompanying notes.

-2-

Prestige Consumer Healthcare Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


(In thousands)	December 31, 2023		March 31, 2023

Assets
Current assets
Cash and cash equivalents	$	63,615	$	58,489
Accounts receivable, net of allowance of $18,710 and $20,205, respectively	174,288		167,016
Inventories	148,637		162,121

Prepaid expenses and other current assets	7,246		4,117

Total current assets	393,786		391,743

Property, plant and equipment, net	70,356		70,412
Operating lease right-of-use assets	10,695		14,923
Finance lease right-of-use assets, net	2,206		4,200
Goodwill	527,878		527,553
Intangible assets, net	2,328,529		2,341,893
Other long-term assets	6,303		3,005

Total Assets	$	3,339,753	$	3,353,729

Liabilities and Stockholders' Equity
Current liabilities

Accounts payable	39,339		62,743
Accrued interest payable	15,197		15,688
Operating lease liabilities, current portion	5,650		6,926
Finance lease liabilities, current portion	2,188		2,834
Other accrued liabilities	65,063		72,524

Total current liabilities	127,437		160,715




Long-term debt, net	1,199,340		1,345,788

Deferred income tax liabilities	397,147		380,434
Long-term operating lease liabilities, net of current portion	6,138		9,876
Long-term finance lease liabilities, net of current portion	195		1,667
Other long-term liabilities	8,919		8,165
Total Liabilities	1,739,176		1,906,645

Commitments and Contingencies — Note 14

Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None	—		—
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 55,329 shares at December 31, 2023 and 54,857 shares at March 31, 2023	553		548
Additional paid-in capital	556,452		535,356
Treasury stock, at cost - 5,680 shares at December 31, 2023 and 5,165 shares at March 31, 2023	(219,638)		(189,114)
Accumulated other comprehensive loss, net of tax	(28,529)		(31,564)
Retained earnings	1,291,739		1,131,858
Total Stockholders' Equity	1,600,577		1,447,084
Total Liabilities and Stockholders' Equity	$	3,339,753	$	3,353,729

See accompanying notes.

-3-

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(Unaudited)


	Three Months Ended December 31, 2023
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at September 30, 2023	55,291	$	552	$	552,369	5,680	$	(219,661)	$	(35,994)	$	1,238,693	$	1,535,959

Stock-based compensation	—	—		2,449		—	—		—		—		2,449
Exercise of stock options	38	1		1,634		—	—		—		—		1,635


Treasury share repurchases	—	—		—		—	23		—		—		23




Net income	—	—		—		—	—		—		53,046		53,046


Comprehensive income	—	—		—		—	—		7,465		—		7,465

Balances at December 31, 2023	55,329	$	553	$	556,452	5,680	$	(219,638)	$	(28,529)	$	1,291,739	$	1,600,577


	Three Months Ended December 31, 2022
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at September 30, 2022	54,690	$	547	$	524,392	5,164	$	(189,098)	$	(36,459)	$	1,320,459	$	1,619,841


Stock-based compensation	—	—		2,433		—	—		—		—		2,433
Exercise of stock options	161	1		5,683		—	—		—		—		5,684

Issuance of shares related to restricted stock	1	—		—		—	—		—		—		—
Treasury share repurchases	—	—		—		1	(16)		—		—		(16)


Net income	—	—		—		—	—		—		51,951		51,951


Comprehensive income	—	—		—		—	—		6,970		—		6,970

Balances at December 31, 2022	54,852	$	548	$	532,508	5,165	$	(189,114)	$	(29,489)	$	1,372,410	$	1,686,863

-4-


	Nine Months Ended December 31, 2023
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at March 31, 2023	54,857	$	548	$	535,356	5,165	$	(189,114)	$	(31,564)	$	1,131,858	$	1,447,084

Stock-based compensation	—	—		10,283		—	—		—		—		10,283
Exercise of stock options	269	3		10,815		—	—		—		—		10,818

Issuance of shares related to restricted stock	203	2		(2)		—	—		—		—		—
Treasury share repurchases	—	—		—		515	(30,524)		—		—		(30,524)




Net income	—	—		—		—	—		—		159,881		159,881


Comprehensive income	—	—		—		—	—		3,035		—		3,035

Balances at December 31, 2023	55,329	$	553	$	556,452	5,680	$	(219,638)	$	(28,529)	$	1,291,739	$	1,600,577


	Nine Months Ended December 31, 2022
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at March 31, 2022	54,430	$	544	$	515,583	4,151	$	(133,648)	$	(19,032)	$	1,214,164	$	1,577,611


Stock-based compensation	—	—		9,756		—	—		—		—		9,756
Exercise of stock options	200	2		7,171		—	—		—		—		7,173

Issuance of shares related to restricted stock	222	2		(2)		—	—		—		—		—
Treasury share repurchases	—	—		—		1,014	(55,466)		—		—		(55,466)


Net income	—	—		—		—	—		—		158,246		158,246


Comprehensive loss	—	—		—		—	—		(10,457)		—		(10,457)

Balances at December 31, 2022	54,852	$	548	$	532,508	5,165	$	(189,114)	$	(29,489)	$	1,372,410	$	1,686,863

See accompanying notes.

-5-

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended December 31,
(In thousands)	2023		2022
Operating Activities
Net income	$	159,881	$	158,246
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,832		24,762

Loss on disposal of property and equipment	231		171
Deferred income taxes	14,892		14,021
Amortization of debt origination costs	3,726		2,613

Stock-based compensation costs	10,283		9,756




Non-cash operating lease cost	4,494		4,697

Other	—		447
Changes in operating assets and liabilities:
Accounts receivable	(7,017)		(17,078)
Inventories	13,790		(38,587)
Prepaid expenses and other current assets	(2,605)		(596)
Accounts payable	(23,964)		8,892
Accrued liabilities	(7,732)		8,345
Operating lease liabilities	(5,259)		(4,941)

Other	(1,533)		(19)
Net cash provided by operating activities	182,019		170,729

Investing Activities
Purchases of property, plant and equipment	(6,407)		(5,226)





Other	1,300		—


Net cash used in investing activities	(5,107)		(5,226)

Financing Activities



Term loan repayments	(150,000)		(55,000)

Borrowings under revolving credit agreement	—		20,000
Repayments under revolving credit agreement	—		(20,000)
Payments of debt costs	(769)		—
Payments of finance leases	(2,112)		(2,058)
Proceeds from exercise of stock options	10,818		7,173


Fair value of shares surrendered as payment of tax withholding	(5,508)		(5,466)
Repurchase of common stock	(25,000)		(50,000)
Net cash used in financing activities	(172,571)		(105,351)

Effects of exchange rate changes on cash and cash equivalents	785		(979)
Increase in cash and cash equivalents	5,126		59,173
Cash and cash equivalents - beginning of period	58,489		27,185
Cash and cash equivalents - end of period	$	63,615	$	86,358

Interest paid	$	49,666	$	36,716
Income taxes paid	$	38,606	$	27,632

See accompanying notes.

-6-

Prestige Consumer Healthcare Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Business and Basis of Presentation

Nature of Business

Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements.

Economic Environment

There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online.

The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, global conflicts and instability, and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely.

Basis of Presentation
The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.

-7-

Recently Adopted Accounting Pronouncements

In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of Topic 848 did not have a material impact on our Consolidated Financial Statements.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

2. Inventories

Inventories consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Components of Inventories
Packaging and raw materials	$	22,093	$	20,634
Work in process	555		220
Finished goods	125,989		141,267

Inventories	$	148,637	$	162,121

Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $5.8 million at both December 31, 2023 and March 31, 2023 related to obsolete and slow-moving inventory.

-8-

3. Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:


(In thousands)		North American OTC Healthcare		International OTC Healthcare		Consolidated
Balance - March 31, 2023
	Goodwill	$	711,452	$	30,204	$	741,656
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - March 31, 2023		498,936		28,617		527,553




	Effects of foreign currency exchange rates	—		325		325
Balance - December 31, 2023
	Goodwill	711,452		30,529		741,981
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - December 31, 2023		$	498,936	$	28,942	$	527,878

The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to goodwill of $48.8 million in our March 31, 2023 financial statements. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties related to future sales, gross margins, and advertising and marketing expenses, which can be impacted by increases in competition, changing consumer preferences, technical advances, supply chain constraints, labor shortages, and inflation. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. If these assumptions are adversely affected, we may be required to record impairment charges in the future. As of December 31, 2023, we determined no events have occurred that would indicate potential impairment of goodwill.

4. Intangible Assets, net

A reconciliation of the activity affecting intangible assets, net is as follows:


(In thousands)	Indefinite- Lived Trademarks		Finite-Lived Trademarks and Customer Relationships		Totals
Gross Carrying Amounts
Balance — March 31, 2023	$	2,168,902	$	411,118	$	2,580,020




Effects of foreign currency exchange rates	1,223		334		1,557
Balance — December 31, 2023	$	2,170,125	$	411,452	$	2,581,577

Accumulated Amortization
Balance — March 31, 2023	$	—	$	238,127	$	238,127

Additions	—		14,842		14,842

Effects of foreign currency exchange rates	—		79		79
Balance — December 31, 2023	$	—	$	253,048	$	253,048

Intangible assets, net - December 31, 2023	$	2,170,125	$	158,404	$	2,328,529

Amortization expense was $4.9 million and $14.8 million for the three and nine months ended December 31, 2023, respectively, and $5.6 million and $16.9 million for the three and nine months ended December 31, 2022, respectively.

Finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and the periods thereafter is as follows (in thousands):

-9-


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ended March 31, 2024)	$	4,947
2025	18,115
2026	16,165
2027	14,574
2028	12,237
Thereafter	92,366
	$	158,404

The date of our annual impairment review was February 28, 2023, and we recorded impairment charges to intangible assets of $321.4 million in our March 31, 2023 financial statements. The assumptions subject to significant uncertainties in the impairment analysis include the discount rate utilized in the analysis, as well as future sales, gross margins, and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record impairment charges in the future. As of December 31, 2023, no events have occurred that would indicate potential impairment of intangible assets.

-10-

5. Leases

We lease real estate and equipment for use in our operations.

The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Finance lease cost:
Amortization of right-of-use assets	$	665	$	665	$	1,994	$	1,994
Interest on lease liabilities	20		41		74		136
Operating lease cost	1,624		1,621		4,872		4,872
Short term lease cost	34		35		101		120
Variable lease cost	14,488		14,727		47,885		43,742

Total net lease cost	$	16,831	$	17,089	$	54,926	$	50,864

As of December 31, 2023, the maturities of lease liabilities were as follows:


(In thousands)
Year Ending March 31,	Operating Leases		Finance Lease		Total
2024 (remaining three months ending March 31, 2024)	$	1,806	$	731	$	2,537
2025	4,834		1,509		6,343
2026	2,348		96		2,444
2027	1,916		80		1,996
2028	1,437		—		1,437
Thereafter	265		—		265
Total undiscounted lease payments	12,606		2,416		15,022
Less amount of lease payments representing interest	(818)		(33)		(851)
Total present value of lease payments	$	11,788	$	2,383	$	14,171

The weighted average remaining lease term and weighted average discount rate were as follows:


		December 31, 2023
Weighted average remaining lease term (years)
	Operating leases	2.95
	Finance leases	1.03
Weighted average discount rate
	Operating leases	3.80	%
	Finance leases	2.93	%

-11-

6. Other Accrued Liabilities

Other accrued liabilities consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Accrued marketing costs	$	29,648	$	30,471
Accrued compensation costs	9,940		14,292
Accrued broker commissions	1,888		1,767
Income taxes payable	5,953		10,645
Accrued professional fees	5,100		4,254

Accrued production costs	4,568		5,700



Other accrued liabilities	7,966		5,395
	$	65,063	$	72,524

7. Long-Term Debt

Long-term debt consists of the following, as of the dates indicated:


(In thousands, except percentages)	December 31, 2023		March 31, 2023

2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031.	$	600,000	$	600,000
2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028.	400,000		400,000

2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at December 31, 2023), due on July 1, 2028.	210,000		360,000



Long-term debt	1,210,000		1,360,000
Less: unamortized debt costs	(10,660)		(14,212)

Long-term debt, net	$	1,199,340	$	1,345,788

At December 31, 2023, we had no balance outstanding on the 2012 ABL Revolver and a borrowing capacity of $168.9 million.

On April 4, 2023, we entered into ABL Amendment No. 8. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate for the 2012 ABL Revolver.

On June 12, 2023, we entered into Term Loan Amendment No. 7, effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate for the 2012 Term Loan.

On December 8, 2023, we entered into Amendment No. 9 ("ABL Amendment No. 9") to the 2012 ABL Revolver. ABL Amendment No. 9 provides for (i) an increase in the aggregate revolving commitment of the facility from $175.0 million to $200.0 million, (ii) an extension of the maturity date of the 2012 ABL Revolver to December 8, 2028, and (iii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including, but not limited to, increased flexibility related to restricted payments, debt incurrence and borrowing base calculations. There were no changes to interest terms as a result of this amendment.

As of December 31, 2023, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans under the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the senior unsecured notes due 2031 (the "2021 Senior Notes") and the senior unsecured notes due 2028 (the "2019 Senior Notes") are as follows:

-12-


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ending March 31, 2024)	$	—
2025	—
2026	—
2027	—
2028	400,000
Thereafter	810,000
	$	1,210,000

8. Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

FASB Accounting Standards Codification ("ASC") 820, Fair Value Measurements, requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2021 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2023 and March 31, 2023.


	December 31, 2023		March 31, 2023
(In thousands)	Carrying Value	Fair Value	Carrying Value	Fair Value
2019 Senior Notes	400,000	391,000	400,000	383,500
2021 Senior Notes	600,000	523,500	600,000	510,750


2012 Term B-5 Loans	210,000	210,263	360,000	359,550

At December 31, 2023 and March 31, 2023, we did not have any assets or liabilities measured in Level 1 or 3.

9. Stockholders' Equity

We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2023.

-13-

On May 2, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0 million of the Company's issued and outstanding common stock through May 31, 2024, utilizing open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the U.S. Securities and Exchange Commission. We completed the repurchase in the first quarter of fiscal 2024.

During the three and nine months ended December 31, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following:


	Three Months Ended December 31,				Nine Months Ended December 31,
	2023		2022		2023	2022
Shares repurchased pursuant to the provisions of the various employee restricted stock awards:
Number of shares	—		303		88,953	99,522
Average price per share	$	—	$50.63		$61.92	$54.92
Total amount repurchased	$	—	$0.02 million		$5.5 million	$5.5 million

Shares repurchased in conjunction with our share repurchase program:
Number of shares	—		—		426,479	914,236
Average price per share	$	—	$	—	$58.62	$54.69
Total amount repurchased	$	—	$	—	$25.0 million	$50.0 million

10. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consisted of the following at December 31, 2023 and March 31, 2023:


(In thousands)	December 31, 2023		March 31, 2023
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(29,245)	$	(32,280)

Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively	716		716
Accumulated other comprehensive loss, net of tax	$	(28,529)	$	(31,564)

As of December 31, 2023 and March 31, 2023, no amounts were reclassified from accumulated other comprehensive loss into earnings.

-14-

11. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator
Net income	$	53,046	$	51,951	$	159,881	$	158,246

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	49,740		49,693		49,731		49,919
Dilutive effect of unvested restricted stock units and options issued to employees and directors	385		493		403		473
Denominator for diluted earnings per share	50,125		50,186		50,134		50,392

Earnings per Common Share:
Basic earnings per share	$	1.07	$	1.05	$	3.21	$	3.17

Diluted earnings per share	$	1.06	$	1.04	$	3.19	$	3.14

For the three months ended December 31, 2023 and 2022, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2023 and 2022, there were 0.3 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

12. Stock-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “2005 Plan”), which provided for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the 2005 Plan, among other changes.

On June 23, 2020, the Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on August 4, 2020, upon the approval of the 2020 Plan by our stockholders. On June 23, 2020, a total of 2,827,210 shares were available for issuance under the 2020 Plan (comprised of 2,000,000 new shares plus 827,210 shares that were unissued under the 2005 Plan). Since the 2020 Plan became effective, all equity awards have been made from the 2020 Plan, and the Company will not grant any additional awards under the 2005 Plan.

-15-

The following table provides information regarding our stock-based compensation:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Pre-tax stock-based compensation costs charged against income	$	2,449	$	2,433	$	10,283	$	9,756
Income tax benefit recognized on compensation costs	$	241	$	49	$	910	$	924
Total fair value of options and RSUs vested during the period	$	—	$	63	$	12,213	$	10,352
Cash received from the exercise of stock options	$	1,635	$	5,684	$	10,818	$	7,173
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$	351	$	731	$	1,490	$	3,626

At December 31, 2023, there were $3.1 million of unrecognized compensation costs related to unvested stock options under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.9 years. At December 31, 2023, there were $12.9 million of unrecognized compensation costs related to unvested RSUs and performance stock units ("PSUs") under the 2005 Plan and the 2020 Plan, excluding an estimate for forfeitures which may occur. We expect to recognize such costs over a weighted average period of 1.7 years.

At December 31, 2023, there were 1.9 million shares available for issuance under the 2020 Plan.

Restricted Stock Units

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:


RSUs	Shares (in thousands)	Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2022
Unvested at March 31, 2022	440.9	$	38.45
Granted	151.0	55.03
Incremental performance shares	42.4	—
Vested	(223.4)	32.09
Forfeited	(1.9)	49.51
Unvested at December 31, 2022	409.0	47.17
Vested at December 31, 2022	108.5	36.54

Nine Months Ended December 31, 2023
Unvested at March 31, 2023	409.0	$	47.17
Granted	157.1	62.06
Incremental performance shares	41.4	—
Vested	(205.0)	43.17
Forfeited	(10.6)	52.68
Unvested at December 31, 2023	391.9	54.43
Vested at December 31, 2023	110.2	38.77

-16-

Options

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:


	Nine Months Ended December 31,
	2023		2022
Expected volatility	30.2% - 31.6%		30.8% - 30.9%
Expected dividends	$	—	$	—
Expected term in years	6.0 to 7.0		6.0 to 7.0
Risk-free rate	3.6% to 4.1%		2.8% to 2.9%
Weighted average grant date fair value of options granted	$	23.79	$	20.10

A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:


Options	Shares (in thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2022
Outstanding at March 31, 2022	1,100.9	$	40.62
Granted	197.6	54.48
Exercised	(200.2)	35.82
Forfeited	(10.3)	49.53
Expired	(0.8)	44.33
Outstanding at December 31, 2022	1,087.2	43.94		6.7	$	20,289
Vested at December 31, 2022	670.5	41.18		5.4	$	14,360

Nine Months Ended December 31, 2023
Outstanding at March 31, 2023	1,081.0	$	43.96
Granted	131.1	61.81
Exercised	(268.9)	40.23
Forfeited	(41.0)	54.15
Expired	(2.8)	54.47
Outstanding at December 31, 2023	899.4	47.18		6.2	$	12,703
Vested at December 31, 2023	606.2	43.23		5.0	$	10,903

The aggregate intrinsic value of options exercised during the nine months ended December 31, 2023 was $5.4 million.

13. Income Taxes

Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.8% and 23.7% for the three months ended December 31, 2023 and 2022, respectively. The effective tax rates used in the calculation of income taxes were 23.4% and 23.0% for the nine months ended December 31, 2023 and 2022, respectively. The increase in the effective tax rate for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation. The increase in the effective tax rate for the nine months ended December 31, 2023, compared to the nine months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation and state tax rate legislative changes.

14. Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine

-17-

whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.

15. Concentrations of Risk

Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2023, approximately 37.0% and 37.8%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2022, approximately 36.9% and 38.7%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 19.0% and 19.6%, respectively, of our gross revenues for the three and nine months ended December 31, 2023. Walmart accounted for approximately 19.9% and 19.8%, respectively, of our gross revenues for the three and nine months ended December 31, 2022. Amazon accounted for approximately 10.7% and 10.4%, respectively, of gross revenues for the three and nine months ended December 31, 2023.

Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations.

At December 31, 2023, we had relationships with 129 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 72.1% of gross sales for the nine months ended December 31, 2023. At December 31, 2022, we had relationships with 133 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 70.5% of gross sales for the nine months ended December 31, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

16. Business Segments

Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and marketing expenses.

The tables below summarize information about our reportable segments.

-18-


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,565	$	46,176	$	282,741
Cost of sales	106,090		18,713		124,803
Gross profit	130,475		27,463		157,938
Advertising and marketing	33,917		5,549		39,466
Contribution margin	$	96,558	$	21,914	$	118,472
Other operating expenses					31,640
Operating income					$	86,832
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	727,131	$	121,235	$	848,366
Cost of sales	323,632		52,103		375,735
Gross profit	403,499		69,132		472,631
Advertising and marketing	100,707		15,092		115,799
Contribution margin	$	302,792	$	54,040	$	356,832
Other operating expenses					96,556
Operating income					$	260,276
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,884	$	38,640	$	275,524
Cost of sales	110,554		14,568		125,122
Gross profit	126,330		24,072		150,402
Advertising and marketing	24,831		5,592		30,423
Contribution margin	$	101,499	$	18,480	$	119,979
Other operating expenses					32,795
Operating income					$	87,184
* Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.

-19-


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	731,456	$	110,400	$	841,856
Cost of sales	327,008		43,318		370,326
Gross profit	404,448		67,082		471,530
Advertising and marketing	99,559		14,634		114,193
Contribution margin	$	304,889	$	52,448	$	357,337
Other operating expenses					98,755
Operating income					$	258,582
* Intersegment revenues of $2.8 million were eliminated from the North American OTC Healthcare segment.

The tables below summarize information about our segment revenues from similar product groups.


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	28,680	$	1,586	$	30,266
Cough & Cold	27,359		5,814		33,173
Women's Health	53,076		5,190		58,266
Gastrointestinal	38,919		22,707		61,626
Eye & Ear Care	38,503		6,569		45,072
Dermatologicals	26,603		1,165		27,768
Oral Care	20,362		3,100		23,462
Other OTC	3,063		45		3,108

Total segment revenues	$	236,565	$	46,176	$	282,741


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	85,838	$	3,814	$	89,652
Cough & Cold	73,703		19,129		92,832
Women's Health	163,031		17,218		180,249
Gastrointestinal	122,303		49,678		171,981
Eye & Ear Care	117,719		17,715		135,434
Dermatologicals	94,299		3,972		98,271
Oral Care	61,400		9,591		70,991
Other OTC	8,838		118		8,956

Total segment revenues	$	727,131	$	121,235	$	848,366

-20-


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	29,396	$	648	$	30,044
Cough & Cold	31,246		6,336		37,582
Women's Health	53,918		4,138		58,056
Gastrointestinal	38,194		18,555		56,749
Eye & Ear Care	32,653		5,229		37,882
Dermatologicals	27,223		978		28,201
Oral Care	21,371		2,738		24,109
Other OTC	2,883		18		2,901

Total segment revenues	$	236,884	$	38,640	$	275,524


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	89,943	$	1,642	$	91,585
Cough & Cold	76,896		19,775		96,671
Women's Health	174,481		13,750		188,231
Gastrointestinal	119,533		48,619		168,152
Eye & Ear Care	109,225		14,699		123,924
Dermatologicals	89,550		2,886		92,436
Oral Care	63,597		8,988		72,585
Other OTC	8,231		41		8,272

Total segment revenues	$	731,456	$	110,400	$	841,856

-21-

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and in future reports filed with the U.S. Securities and Exchange Commission ("SEC").


See also “Cautionary Statement Regarding Forward-Looking Statements” on page 31 of this Quarterly Report on Form 10-Q.

Unless otherwise indicated by the context, all references in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Similarly, references to a year (e.g., 2024) refers to our fiscal year ended March 31 of that year.

General

We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") healthcare products to mass merchandisers, drug, food, dollar, convenience, and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage.

We have grown our brand portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a core brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.

Economic Environment

-22-

Results of Operations

Three Months Ended December 31, 2023 compared to the Three Months Ended December 31, 2022

Total Segment Revenues

The following table represents total revenue by segment, including product groups, for the three months ended December 31, 2023 and 2022.


	Three Months Ended December 31,
							Increase (Decrease)
(In thousands)	2023		%	2022		%	Amount		%
North American OTC Healthcare
Analgesics	$	28,680	10.1	$	29,396	10.7	$	(716)	(2.4)
Cough & Cold	27,359		9.7	31,246		11.3	(3,887)		(12.4)
Women's Health	53,076		18.9	53,918		19.5	(842)		(1.6)
Gastrointestinal	38,919		13.7	38,194		13.9	725		1.9
Eye & Ear Care	38,503		13.6	32,653		11.9	5,850		17.9
Dermatologicals	26,603		9.4	27,223		9.9	(620)		(2.3)
Oral Care	20,362		7.2	21,371		7.8	(1,009)		(4.7)
Other OTC	3,063		1.1	2,883		1.0	180		6.2
Total North American OTC Healthcare	236,565		83.7	236,884		86.0	(319)		(0.1)

International OTC Healthcare
Analgesics	$	1,586	0.6	$	648	0.2	938		144.8
Cough & Cold	5,814		2.1	6,336		2.3	(522)		(8.2)
Women's Health	5,190		1.8	4,138		1.5	1,052		25.4
Gastrointestinal	22,707		8.0	18,555		6.6	4,152		22.4
Eye & Ear Care	6,569		2.3	5,229		2.0	1,340		25.6
Dermatologicals	1,165		0.4	978		0.4	187		19.1
Oral Care	3,100		1.1	2,738		1.0	362		13.2
Other OTC	45		—	18		—	27		150.0
Total International OTC Healthcare	46,176		16.3	38,640		14.0	7,536		19.5



Total Consolidated	$	282,741	100.0	$	275,524	100.0	$	7,217	2.6

Total revenues for the three months ended December 31, 2023 were $282.7 million, an increase of $7.2 million, or 2.6%, versus the three months ended December 31, 2022.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $0.3 million, or 0.1%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. The $0.3 million decrease was primarily attributable to a decline in sales in the Cough & Cold and Oral Care categories, partly offset by an increase in sales in the Eye & Ear Care category.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $7.5 million, or 19.5%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. The $7.5 million increase was primarily attributable to an increase in sales in the Gastrointestinal, Eye & Ear Care and Women's Health categories.

-23-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.


	Three Months Ended December 31,
(In thousands)							Increase (Decrease)
Gross Profit	2023		%	2022		%	Amount		%
North American OTC Healthcare	$	130,475	55.2	$	126,330	53.3	$	4,145	3.3
International OTC Healthcare	27,463		59.5	24,072		62.3	3,391		14.1

	$	157,938	55.9	$	150,402	54.6	$	7,536	5.0

Gross profit for the three months ended December 31, 2023 increased $7.5 million, or 5.0%, when compared with the three months ended December 31, 2022. As a percentage of total revenues, gross profit increased to 55.9% during the three months ended December 31, 2023, from 54.6% during the three months ended December 31, 2022, primarily due to reduced logistics costs in our North American OTC Healthcare segment.

North American OTC Healthcare Segment

Gross profit for the North American OTC Healthcare segment increased $4.1 million, or 3.3%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. As a percentage of North American OTC Healthcare revenues, gross profit increased to 55.2% during the three months ended December 31, 2023 from 53.3% during the three months ended December 31, 2022, primarily due to reduced logistics costs.

International OTC Healthcare Segment

Gross profit for the International OTC Healthcare segment increased $3.4 million, or 14.1%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. As a percentage of International OTC Healthcare revenues, gross profit decreased to 59.5% during the three months ended December 31, 2023 from 62.3% during the three months ended December 31, 2022, primarily due to increased supply chain costs and product mix.

Contribution Margin

Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.

The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.


	Three Months Ended December 31,
(In thousands)							Increase (Decrease)
Contribution Margin	2023		%	2022		%	Amount		%
North American OTC Healthcare	$	96,558	40.8	$	101,499	42.8	$	(4,941)	(4.9)
International OTC Healthcare	21,914		47.5	18,480		47.8	3,434		18.6

	$	118,472	41.9	$	119,979	43.5	$	(1,507)	(1.3)

North American OTC Healthcare Segment

Contribution margin for the North American OTC Healthcare segment decreased $4.9 million, or 4.9%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. As a percentage of North American OTC Healthcare revenues, contribution margin decreased to 40.8% during the three months ended December 31, 2023 from 42.8% during the three months ended December 31, 2022. The contribution margin decrease as a percentage of revenues was primarily due to an increase in advertising and marketing spend in the three months ended December 31, 2023, partly offset by the increase in gross profit margin noted above.

International OTC Healthcare Segment

Contribution margin for the International OTC Healthcare segment increased $3.4 million, or 18.6%, during the three months ended December 31, 2023 versus the three months ended December 31, 2022. As a percentage of International OTC Healthcare revenues, contribution margin decreased to 47.5% during the three months ended December 31, 2023 from 47.8% during the three months ended December 31, 2022. The contribution margin decrease as a percentage of revenues was primarily due to the decrease in gross profit margin noted above.

-24-

General and Administrative

General and administrative expenses were $26.0 million for the three months ended December 31, 2023 and $26.5 million for the three months ended December 31, 2022.

Depreciation and Amortization

Depreciation and amortization expenses decreased to $5.6 million for the three months ended December 31, 2023 from $6.3 million for the three months ended December 31, 2022. The decrease in depreciation and amortization expenses was primarily attributable to a decrease in amortization expense due to impairment charges taken on finite-lived brands in fiscal 2023.

Interest Expense, Net

Interest expense, net was $16.6 million during the three months ended December 31, 2023 versus $17.9 million during the three months ended December 31, 2022. The average indebtedness decreased to $1.3 billion during the three months ended December 31, 2023 from $1.4 billion during the three months ended December 31, 2022. The average cost of borrowing increased to 5.4% for the three months ended December 31, 2023 from 5.0% for the three months ended December 31, 2022.

Income Taxes

The provision for income taxes during the three months ended December 31, 2023 was $16.5 million versus $16.2 million during the three months ended December 31, 2022. The effective tax rate during the three months ended December 31, 2023 was 23.8% versus 23.7% during the three months ended December 31, 2022. The increase in the effective tax rate for the three months ended December 31, 2023 was due to the impact of discrete items primarily pertaining to stock-based compensation.

-25-

Results of Operations

Nine Months Ended December 31, 2023 compared to the Nine Months Ended December 31, 2022

Total Segment Revenues

The following table represents total revenue by segment, including product groups, for the nine months ended December 31, 2023 and 2022.


	Nine Months Ended December 31,
							Increase (Decrease)
(In thousands)	2023		%	2022		%	Amount		%
North American OTC Healthcare
Analgesics	$	85,838	10.1	$	89,943	10.7	$	(4,105)	(4.6)
Cough & Cold	73,703		8.7	76,896		9.1	(3,193)		(4.2)
Women's Health	163,031		19.3	174,481		20.7	(11,450)		(6.6)
Gastrointestinal	122,303		14.4	119,533		14.2	2,770		2.3
Eye & Ear Care	117,719		13.9	109,225		13.0	8,494		7.8
Dermatologicals	94,299		11.1	89,550		10.6	4,749		5.3
Oral Care	61,400		7.2	63,597		7.6	(2,197)		(3.5)
Other OTC	8,838		1.0	8,231		1.0	607		7.4
Total North American OTC Healthcare	727,131		85.7	731,456		86.9	(4,325)		(0.6)

International OTC Healthcare
Analgesics	$	3,814	0.4	$	1,642	0.2	2,172		132.3
Cough & Cold	19,129		2.3	19,775		2.4	(646)		(3.3)
Women's Health	17,218		2.0	13,750		1.6	3,468		25.2
Gastrointestinal	49,678		5.9	48,619		5.8	1,059		2.2
Eye & Ear Care	17,715		2.1	14,699		1.7	3,016		20.5
Dermatologicals	3,972		0.5	2,886		0.3	1,086		37.6
Oral Care	9,591		1.1	8,988		1.1	603		6.7
Other OTC	118		—	41		—	77		187.8
Total International OTC Healthcare	121,235		14.3	110,400		13.1	10,835		9.8



Total Consolidated	$	848,366	100.0	$	841,856	100.0	$	6,510	0.8

Total revenues for the nine months ended December 31, 2023 were $848.4 million, an increase of $6.5 million, or 0.8%, versus the nine months ended December 31, 2022.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $4.3 million, or 0.6%, during the nine months ended December 31, 2023 versus the nine months ended December 31, 2022. The $4.3 million decrease was primarily attributable to a decrease in sales in the Women's Health, Analgesics and Cough & Cold categories, partly offset by an increase in sales in the Eye & Ear Care, Dermatologicals, and Gastrointestinal categories.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $10.8 million, or 9.8%, during the nine months ended December 31, 2023 versus the nine months ended December 31, 2022. The $10.8 million increase was mainly attributable to an increase in sales in the Women's Health, Eye & Ear Care and Analgesics categories.

-26-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.


	Nine Months Ended December 31,
(In thousands)							Increase (Decrease)
Gross Profit	2023		%	2022		%	Amount		%
North American OTC Healthcare	$	403,499	55.5	$	404,448	55.3	$	(949)	(0.2)
International OTC Healthcare	69,132		57.0	67,082		60.8	2,050		3.1

	$	472,631	55.7	$	471,530	56.0	$	1,101	0.2

Gross profit for the nine months ended December 31, 2023 increased $1.1 million, or 0.2%, when compared with the nine months ended December 31, 2022. As a percentage of total revenues, gross profit decreased to 55.7% during the nine months ended December 31, 2023, from 56.0% during the nine months ended December 31, 2022, primarily due to increased supply chain costs and product mix, partly offset by pricing actions.

North American OTC Healthcare Segment

Gross profit for the North American OTC Healthcare segment decreased $0.9 million, or 0.2%, during the nine months ended December 31, 2023 versus the nine months ended December 31, 2022. As a percentage of North American OTC Healthcare revenues, gross profit increased to 55.5% during the nine months ended December 31, 2023 from 55.3% during the nine months ended December 31, 2022, primarily due to product mix and pricing actions, partly offset by increased supply chain costs.

International OTC Healthcare Segment

Gross profit for the International OTC Healthcare segment increased $2.1 million, or 3.1%, during the nine months ended December 31, 2023 versus the nine months ended December 31, 2022. As a percentage of International OTC Healthcare revenues, gross profit decreased to 57.0% during the nine months ended December 31, 2023 from 60.8% during the nine months ended December 31, 2022, primarily due to increased supply chain costs and product mix.

Contribution Margin

Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.

The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.


	Nine Months Ended December 31,
(In thousands)							Increase (Decrease)
Contribution Margin	2023		%	2022		%	Amount		%
North American OTC Healthcare	$	302,792	41.6	$	304,889	41.7	$	(2,097)	(0.7)
International OTC Healthcare	54,040		44.6	52,448		47.5	1,592		3.0

	$	356,832	42.1	$	357,337	42.4	$	(505)	(0.1)

North American OTC Healthcare Segment

Contribution margin for the North American OTC Healthcare segment for the nine months ended December 31, 2023 decreased $2.1 million, or 0.7%, when compared with the nine months ended December 31, 2022. As a percentage of North American OTC Healthcare revenues, contribution margin decreased slightly to 41.6% during the nine months ended December 31, 2023 from 41.7% during the nine months ended December 31, 2022, primarily due to a slight increase in advertising and marketing spend in the nine months ended December 31, 2023.

International OTC Healthcare Segment

Contribution margin for the International OTC Healthcare segment increased $1.6 million, or 3.0%, during the nine months ended December 31, 2023 versus the nine months ended December 31, 2022. As a percentage of International OTC Healthcare revenues, contribution margin decreased to 44.6% during the nine months ended December 31, 2023 from 47.5% during the nine months ended December 31, 2022. The contribution margin decrease as a percentage of revenues was primarily due to the decrease in gross profit margin noted above.

-27-

General and Administrative

General and administrative expenses remained flat at $79.7 million for the nine months ended December 31, 2023 and nine months ended December 31, 2022.

Depreciation and Amortization

Depreciation and amortization expenses were $16.9 million for the nine months ended December 31, 2023 and $19.1 million for the nine months ended December 31, 2022. The decrease in depreciation and amortization expenses was primarily attributable to a decrease in amortization expense due to impairment charges taken on finite-lived brands in fiscal 2023.

Interest Expense, Net

Interest expense, net was $51.9 million during the nine months ended December 31, 2023 versus $50.2 million during the nine months ended December 31, 2022. The average indebtedness decreased to $1.3 billion during the nine months ended December 31, 2023 from $1.5 billion during the nine months ended December 31, 2022. The average cost of borrowing increased to 5.4% for the nine months ended December 31, 2023 compared to 4.5% for the nine months ended December 31, 2022.

Income Taxes

The provision for income taxes during the nine months ended December 31, 2023 was $48.8 million versus $47.4 million during the nine months ended December 31, 2022. The effective tax rate during the nine months ended December 31, 2023 was 23.4% versus 23.0% during the nine months ended December 31, 2022. The increase in the effective tax rate for the nine months ended December 31, 2023 compared to the nine months ended December 31, 2022 was due to the impact of discrete items primarily pertaining to stock-based compensation and state tax rate legislative changes.

Liquidity and Capital Resources

Liquidity

Our primary source of cash comes from our cash flow from operations. In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions. We have financed our operations, and expect to continue to finance our operations for the next twelve months and the foreseeable future, with a combination of funds generated from operations and borrowings. Our principal uses of cash are for operating expenses, debt service, share repurchases, capital expenditures, and acquisitions. Based on our current levels of operations and anticipated growth, excluding acquisitions, we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months. See "Economic Environment" above.

As of December 31, 2023, we had cash and cash equivalents of $63.6 million, an increase of $5.1 million from March 31, 2023. The following table summarizes the change:


	Nine Months Ended December 31,
(In thousands)	2023		2022		$ Change
Cash provided by (used in):
Operating Activities	$	182,019	$	170,729	$	11,290
Investing Activities	(5,107)		(5,226)		119
Financing Activities	(172,571)		(105,351)		(67,220)
Effects of exchange rate changes on cash and cash equivalents	785		(979)		1,764
Net change in cash and cash equivalents	$	5,126	$	59,173	$	(54,047)

Operating Activities

Net cash provided by operating activities was $182.0 million for the nine months ended December 31, 2023, compared to $170.7 million for the nine months ended December 31, 2022. The $11.3 million increase was primarily due to decreased working capital.

Investing Activities

Net cash used in investing activities was $5.1 million for the nine months ended December 31, 2023, compared to $5.2 million for the nine months ended December 31, 2022.

-28-

Financing Activities

Net cash used in financing activities was $172.6 million for the nine months ended December 31, 2023, compared to $105.4 million for the nine months ended December 31, 2022. The $67.2 million increase was primarily due to net repayments of $95.0 million compared to the prior year nine month period, partly offset by a decrease in the repurchase of shares of our common stock in conjunction with our share repurchase program of $25.0 million in the nine months ended December 31, 2023.

Capital Resources

As of December 31, 2023, we had an aggregate of $1.2 billion of outstanding indebtedness, which consisted of the following:

•$400.0 million of 5.125% 2019 senior unsecured notes, which mature on January 15, 2028 (the "2019 Senior Notes");

•$600.0 million of 3.750% 2021 senior unsecured notes, which mature on April 1, 2031 (the "2021 Senior Notes"); and

•$210.0 million of borrowings under the Term B-5 Loans under our term loan originally entered into on January 31, 2012 (the "2012 Term Loan”) due July 1, 2028.

As of December 31, 2023, we had no outstanding balance on our asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver”) and a borrowing capacity of $168.9 million.

Since we have made optional payments that exceed all of our required quarterly payments, we will not be required to make another payment on the 2012 Term Loan until maturity.

Maturities:


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ending March 31, 2024)	$	—
2025	—
2026	—
2027	—
2028	400,000
Thereafter	810,000
	$	1,210,000

Covenants:

Our debt facilities contain various financial covenants, including provisions that require us to maintain certain leverage, interest coverage and fixed charge ratios. The credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2021 Senior Notes and 2019 Senior Notes contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payments of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:

•Have a leverage ratio of less than 6.50 to 1.0 for the quarter ended December 31, 2023 and thereafter (defined as, with certain adjustments, the ratio of our consolidated total net debt as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges and certain other items (“EBITDA”));

•Have an interest coverage ratio of greater than 2.25 to 1.0 for the quarter ended December 31, 2023 and thereafter (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense); and

-29-

•Have a fixed charge ratio of greater than 1.0 to 1.0 for the quarter ended December 31, 2023 (defined as, with certain adjustments, the ratio of our consolidated EBITDA minus capital expenditures to our trailing twelve month consolidated interest paid, taxes paid and other specified payments). Our fixed charge requirement remains level throughout the term of the debt facilities.

At December 31, 2023, we were in compliance with the applicable financial and restrictive covenants under the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2021 Senior Notes and the 2019 Senior Notes. Management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the next twelve months.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. A summary of our critical accounting policies is presented in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. There were no material changes to our critical accounting policies during the nine months ended December 31, 2023.

Recent Accounting Pronouncements

A description of recently issued and recently adopted accounting pronouncements is included in the notes to the unaudited Condensed Consolidated Financial Statements in Part I, Item I, Note 1 of this Quarterly Report on Form 10-Q.

-30-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA.

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” "plan," “project,” "intend," "strategy," "goal," "objective," "future," "seek," "may," "might," "should," "would," "will," "will be," or other similar words and phrases. Forward-looking statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation:

•Price increases for raw materials, labor, energy and transportation costs, and for other input costs;

•Disruptions of supply of sourced goods or components;

•The impact of geopolitical events and severe illness outbreaks on global economic conditions, consumer demand, retailer product availability, and business operations including manufacturing, supply chain and distribution;

•The high level of competition in our industry and markets;

•The level of success of new product introductions, line extensions, increased spending on advertising and marketing support, and other new sales and marketing strategies;

•Our dependence on a limited number of customers for a large portion of our sales;

•Our inability to successfully identify, negotiate, complete and integrate suitable acquisition candidates and to obtain necessary financing;

•Changes by retailers in inventory management practices, delivery requirements, and demands for marketing and promotional spending in order to retain or increase shelf space or online share;

•Our inability to grow our international sales;

•General economic conditions and incidence levels affecting sales of our products and their respective markets;

•Financial factors, such as increases in interest rates and currency exchange rate fluctuations;

•Changing consumer trends, additional store brand or branded competition, accelerating shifts to online shopping or pricing pressures;

•Our dependence on third-party manufacturers to produce many of the products we sell and our ability to transfer production to our own facilities or other third-party suppliers;

•Our dependence on third-party logistics providers to distribute our products to customers;

•Disruptions in our distribution center or manufacturing facility;

•Potential changes in export/import and trade laws, regulations and policies including any increased trade restrictions or tariffs;

•Acquisitions, dispositions or other strategic transactions diverting managerial resources and creating additional liabilities;

•Actions of government agencies in connection with our manufacturing plant, products, advertising or regulatory matters;

•Product liability claims, product recalls and related negative publicity;

•Our inability to protect our intellectual property rights;

•Our dependence on third parties for intellectual property relating to some of the products we sell;

•Our inability to protect our information technology systems from threats or disruptions;

•Our dependence on third-party information technology service providers and their ability to protect against security threats and disruptions;

•Our assets being comprised virtually entirely of goodwill and intangibles and possible changes in their value based on adverse operating results and/or changes in the discount rate used to value our brands;

•Our dependence on key personnel;

•The costs associated with any claims in litigation or arbitration and any adverse judgments rendered in such litigation or arbitration;

•Our level of indebtedness and possible inability to service our debt or to obtain additional financing;

-31-

•The restrictions imposed by our financing agreements on our operations; and

•Changes in federal, state and other geographic tax laws.

For more information, see Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.

-32-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

We are exposed to changes in interest rates because our 2012 Term Loan and 2012 ABL Revolver are variable rate debt. At December 31, 2023, approximately $210.0 million of our debt carries a variable rate of interest.

Holding other variables constant, including levels of indebtedness, a 1.0% increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the three and nine months ended December 31, 2023 of approximately $0.7 million and $2.3 million, respectively.

Foreign Currency Exchange Rate Risk

During the three and nine months ended December 31, 2023, approximately 17.0% and 14.1%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. During the three and nine months ended December 31, 2022, approximately 14.9% and 13.8%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. As such, we are exposed to transactions that are sensitive to foreign currency exchange rates. These transactions are primarily with respect to the Canadian and Australian Dollars.

We performed a sensitivity analysis with respect to exchange rates for the three and nine months ended December 31, 2023 and 2022. Holding all other variables constant, and assuming a hypothetical 10.0% adverse change in foreign currency exchange rates, this analysis resulted in a less than 5.0% impact on pre-tax income of approximately $2.7 million for the three months ended December 31, 2023 and approximately $6.8 million for the nine months ended December 31, 2023. It represented a less than 5.0% impact on pre-tax income of approximately $2.3 million for the three months ended December 31, 2022 and $7.1 million for the nine months ended December 31, 2022.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of December 31, 2023. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2023, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

You should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2023, which could materially affect our business, financial condition or results of operations. The risk factors described in our Annual Report on Form 10-K have not materially changed in the period covered by this Quarterly Report on Form 10-Q, but such risks are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations.

Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for

-33-

any particular future period may decrease. In the future, operating results may fall below the expectations of securities analysts and investors. In that event, the market price of our outstanding securities could be adversely impacted.

-34-

ITEM 6. EXHIBITS



3.1						Amended and Restated Certificate of Incorporation of Prestige Consumer Healthcare Inc. (filed as Exhibit 3.1 to the Company's Form S-1/A filed with the SEC on February 8, 2005).*

3.1.1						Amendment to Amended and Restated Certificate of Incorporation of Prestige Consumer Healthcare Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 2, 2018).*

3.2						Amended and Restated Bylaws of Prestige Consumer Healthcare Inc., as amended, effective October 29, 2018 (filed as Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed with the SEC on February 7, 2019).*

10.1						Amendment No. 9, dated as of December 8, 2023, to the ABL Credit Agreement, originally dated as of January 31, 2012, among the Company, Prestige Brands, Inc., the other guarantors from time to time party thereto, the lenders from time to time party thereto and Citibank, N.A., as administrative agent, L/C issue and swing line lender (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2023).*

31.1						Certification of Principal Executive Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2						Certification of Principal Financial Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1						Certification of Principal Executive Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

32.2						Certification of Principal Financial Officer of Prestige Consumer Healthcare Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

*						Incorporated herein by reference.

101.INS						Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

-35-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRESTIGE CONSUMER HEALTHCARE INC.

Date:

February 8, 2024

By:

/s/ Christine Sacco

Christine Sacco

Chief Financial Officer

(Principal Financial Officer and Duly Authorized Officer)

-36-

Exhibit 31.1

CERTIFICATIONS

I, Ronald M. Lombardi, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Prestige Consumer Healthcare Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:	February 8, 2024	/s/ Ronald M. Lombardi
		Ronald M. Lombardi
		Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.2

CERTIFICATIONS

I, Christine Sacco, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Prestige Consumer Healthcare Inc.;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:	February 8, 2024	/s/ Christine Sacco
		Christine Sacco
		Chief Financial Officer
		(Principal Financial Officer)

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ronald M. Lombardi, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Consumer Healthcare Inc. on Form 10-Q for the quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Consumer Healthcare Inc.


						/s/ Ronald M. Lombardi
						Name: Ronald M. Lombardi
						Title: Chief Executive Officer
						(Principal Executive Officer)
						Date: February 8, 2024

EXHIBIT 32.2

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Christine Sacco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Consumer Healthcare Inc. on Form 10-Q for the quarter ended December 31, 2023, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Consumer Healthcare Inc.


						/s/ Christine Sacco
						Name: Christine Sacco
						Title: Chief Financial Officer
						(Principal Financial Officer)
						Date: February 8, 2024

Cover Page - shares	9 Months Ended
Cover Page - shares	Dec. 31, 2023	Feb. 02, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,649,288
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Cost of Sales
Cost of sales excluding depreciation	122,794	123,251	369,772	364,631
Cost of sales depreciation	2,009	1,871	5,963	5,695
Cost of sales	124,803	125,122	375,735	370,326
Gross profit	157,938	150,402	472,631	471,530
Operating Expenses
Advertising and marketing	39,466	30,423	115,799	114,193
General and administrative	26,003	26,536	79,687	79,688
Depreciation and amortization	5,637	6,259	16,869	19,067
Total operating expenses	71,106	63,218	212,355	212,948
Operating income	86,832	87,184	260,276	258,582
Other expense
Interest expense, net	16,575	17,917	51,900	50,188
Other expense (income), net	682	1,150	(327)	2,787
Total other expense, net	17,257	19,067	51,573	52,975
Income before income taxes	69,575	68,117	208,703	205,607
Provision for income taxes	16,529	16,166	48,822	47,361
Net income	$ 53,046	$ 51,951	$ 159,881	$ 158,246
Earnings per share:
Basic (in USD per share)	$ 1.07	$ 1.05	$ 3.21	$ 3.17
Diluted (in USD per share)	$ 1.06	$ 1.04	$ 3.19	$ 3.14
Weighted average shares outstanding:
Basic (in shares)	49,740	49,693	49,731	49,919
Diluted (in shares)	50,125	50,186	50,134	50,392
Comprehensive income, net of tax:
Currency translation adjustments	$ 7,465	$ 6,970	$ 3,035	$ (9,667)
Net loss on termination of pension plan	0	0	0	(790)
Total other comprehensive income (loss)	7,465	6,970	3,035	(10,457)
Comprehensive income	60,511	58,921	162,916	147,789
Net sales
Revenues
Total revenues	282,715	275,495	848,321	841,783
Other revenues
Revenues
Total revenues	$ 26	$ 29	$ 45	$ 73

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets
Cash and cash equivalents	$ 63,615	$ 58,489
Accounts receivable, net of allowance of $18,710 and $20,205, respectively	174,288	167,016
Inventories	148,637	162,121
Prepaid expenses and other current assets	7,246	4,117
Total current assets	393,786	391,743
Property, plant and equipment, net	70,356	70,412
Operating lease right-of-use assets	10,695	14,923
Finance lease right-of-use assets, net	2,206	4,200
Goodwill	527,878	527,553
Intangible assets, net	2,328,529	2,341,893
Other long-term assets	6,303	3,005
Total Assets	3,339,753	3,353,729
Current liabilities
Accounts payable	39,339	62,743
Accrued interest payable	15,197	15,688
Operating lease liabilities, current portion	5,650	6,926
Finance lease liabilities, current portion	2,188	2,834
Other accrued liabilities	65,063	72,524
Total current liabilities	127,437	160,715
Long-term debt, net	1,199,340	1,345,788
Deferred income tax liabilities	397,147	380,434
Long-term operating lease liabilities, net of current portion	6,138	9,876
Long-term finance lease liabilities, net of current portion	195	1,667
Other long-term liabilities	8,919	8,165
Total Liabilities	1,739,176	1,906,645
Commitments and Contingencies — Note 14
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 55,291 shares at September 30, 2023 and 54,857 shares at March 31, 2023	553	548
Additional paid-in capital	556,452	535,356
Treasury stock, at cost - 5,680 shares at December 31, 2023 and 5,165 shares at March 31, 2023	(219,638)	(189,114)
Accumulated other comprehensive loss, net of tax	(28,529)	(31,564)
Retained earnings	1,291,739	1,131,858
Total Stockholders' Equity	1,600,577	1,447,084
Total Liabilities and Stockholders' Equity	$ 3,339,753	$ 3,353,729

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 18,710	$ 20,205
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	55,329,000	54,857,000
Treasury stock (in shares)	5,680,000	5,165,000

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2022		54,430,000
Equity, beginning balance at Mar. 31, 2022	$ 1,577,611	$ 544	$ 515,583	$ (133,648)	$ (19,032)	$ 1,214,164
Treasury stock, beginning balance (in shares) at Mar. 31, 2022				4,151,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 9,756		9,756
Exercise of stock options (in shares)	200,200	200,000
Exercise of stock options	$ 7,173	$ 2	7,171
Issuance of shares related to restricted stock (in shares)		222,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				1,014,000
Treasury share repurchases	(55,466)			$ (55,466)
Net income	158,246					158,246
Comprehensive income	(10,457)				(10,457)
Common stock, ending balance (in shares) at Dec. 31, 2022		54,852,000
Equity, ending balance at Dec. 31, 2022	1,686,863	$ 548	532,508	$ (189,114)	(29,489)	1,372,410
Treasury stock, ending balance (in shares) at Dec. 31, 2022				5,165,000
Common stock, beginning balance (in shares) at Sep. 30, 2022		54,690,000
Equity, beginning balance at Sep. 30, 2022	1,619,841	$ 547	524,392	$ (189,098)	(36,459)	1,320,459
Treasury stock, beginning balance (in shares) at Sep. 30, 2022				5,164,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,433		2,433
Exercise of stock options (in shares)		161,000
Exercise of stock options	5,684	$ 1	5,683
Issuance of shares related to restricted stock (in shares)		1,000
Issuance of shares related to restricted stock	0
Treasury share repurchases (in shares)				1,000
Treasury share repurchases	(16)			$ (16)
Net income	51,951					51,951
Comprehensive income	6,970				6,970
Common stock, ending balance (in shares) at Dec. 31, 2022		54,852,000
Equity, ending balance at Dec. 31, 2022	1,686,863	$ 548	532,508	$ (189,114)	(29,489)	1,372,410
Treasury stock, ending balance (in shares) at Dec. 31, 2022				5,165,000
Common stock, beginning balance (in shares) at Mar. 31, 2023		54,857,000
Equity, beginning balance at Mar. 31, 2023	$ 1,447,084	$ 548	535,356	$ (189,114)	(31,564)	1,131,858
Treasury stock, beginning balance (in shares) at Mar. 31, 2023	5,165,000			5,165,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 10,283		10,283
Exercise of stock options (in shares)	268,900	269,000
Exercise of stock options	$ 10,818	$ 3	10,815
Issuance of shares related to restricted stock (in shares)		203,000
Issuance of shares related to restricted stock	0	$ 2	(2)
Treasury share repurchases (in shares)				515,000
Treasury share repurchases	(30,524)			$ (30,524)
Net income	159,881					159,881
Comprehensive income	3,035				3,035
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	$ 1,600,577	$ 553	556,452	$ (219,638)	(28,529)	1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023	5,680,000			5,680,000
Common stock, beginning balance (in shares) at Sep. 30, 2023		55,291,000
Equity, beginning balance at Sep. 30, 2023	$ 1,535,959	$ 552	552,369	$ (219,661)	(35,994)	1,238,693
Treasury stock, beginning balance (in shares) at Sep. 30, 2023				5,680,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,449		2,449
Exercise of stock options (in shares)		38,000
Exercise of stock options	1,635	$ 1	1,634
Treasury share repurchases	23			$ 23
Net income	53,046					53,046
Comprehensive income	7,465				7,465
Common stock, ending balance (in shares) at Dec. 31, 2023		55,329,000
Equity, ending balance at Dec. 31, 2023	$ 1,600,577	$ 553	$ 556,452	$ (219,638)	$ (28,529)	$ 1,291,739
Treasury stock, ending balance (in shares) at Dec. 31, 2023	5,680,000			5,680,000

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Activities
Net income	$ 159,881	$ 158,246
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,832	24,762
Loss on disposal of property and equipment	231	171
Deferred income taxes	14,892	14,021
Amortization of debt origination costs	3,726	2,613
Stock-based compensation costs	10,283	9,756
Non-cash operating lease cost	4,494	4,697
Other	0	447
Changes in operating assets and liabilities:
Accounts receivable	(7,017)	(17,078)
Inventories	13,790	(38,587)
Prepaid expenses and other current assets	(2,605)	(596)
Accounts payable	(23,964)	8,892
Accrued liabilities	(7,732)	8,345
Operating lease liabilities	(5,259)	(4,941)
Other	(1,533)	(19)
Net cash provided by operating activities	182,019	170,729
Investing Activities
Purchases of property, plant and equipment	(6,407)	(5,226)
Other	1,300	0
Net cash used in investing activities	(5,107)	(5,226)
Financing Activities
Term loan repayments	(150,000)	(55,000)
Borrowings under revolving credit agreement	0	20,000
Repayments under revolving credit agreement	0	(20,000)
Payments of debt costs	(769)	0
Payments of finance leases	(2,112)	(2,058)
Proceeds from exercise of stock options	10,818	7,173
Fair value of shares surrendered as payment of tax withholding	(5,508)	(5,466)
Repurchase of common stock	(25,000)	(50,000)
Net cash used in financing activities	(172,571)	(105,351)
Effects of exchange rate changes on cash and cash equivalents	785	(979)
Increase in cash and cash equivalents	5,126	59,173
Cash and cash equivalents - beginning of period	58,489	27,185
Cash and cash equivalents - end of period	63,615	86,358
Supplemental Cash Flow Information
Interest paid	49,666	36,716
Income taxes paid	$ 38,606	$ 27,632

Business and Basis of Presentation	9 Months Ended
Business and Basis of Presentation	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 7 to these Condensed Consolidated Financial Statements. Economic Environment There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online. The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including global supply chain constraints, inflation, global conflicts and instability, and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of Topic 848 did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

Inventories

9 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Components of Inventories
Packaging and raw materials	$	22,093	$	20,634
Work in process	555		220
Finished goods	125,989		141,267

Inventories	$	148,637	$	162,121

Goodwill

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:


(In thousands)		North American OTC Healthcare		International OTC Healthcare		Consolidated
Balance - March 31, 2023
	Goodwill	$	711,452	$	30,204	$	741,656
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - March 31, 2023		498,936		28,617		527,553




	Effects of foreign currency exchange rates	—		325		325
Balance - December 31, 2023
	Goodwill	711,452		30,529		741,981
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - December 31, 2023		$	498,936	$	28,942	$	527,878

Intangible Assets, net

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, net

A reconciliation of the activity affecting intangible assets, net is as follows:


(In thousands)	Indefinite- Lived Trademarks		Finite-Lived Trademarks and Customer Relationships		Totals
Gross Carrying Amounts
Balance — March 31, 2023	$	2,168,902	$	411,118	$	2,580,020




Effects of foreign currency exchange rates	1,223		334		1,557
Balance — December 31, 2023	$	2,170,125	$	411,452	$	2,581,577

Accumulated Amortization
Balance — March 31, 2023	$	—	$	238,127	$	238,127

Additions	—		14,842		14,842

Effects of foreign currency exchange rates	—		79		79
Balance — December 31, 2023	$	—	$	253,048	$	253,048

Intangible assets, net - December 31, 2023	$	2,170,125	$	158,404	$	2,328,529


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ended March 31, 2024)	$	4,947
2025	18,115
2026	16,165
2027	14,574
2028	12,237
Thereafter	92,366
	$	158,404

Leases

9 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

We lease real estate and equipment for use in our operations.

The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Finance lease cost:
Amortization of right-of-use assets	$	665	$	665	$	1,994	$	1,994
Interest on lease liabilities	20		41		74		136
Operating lease cost	1,624		1,621		4,872		4,872
Short term lease cost	34		35		101		120
Variable lease cost	14,488		14,727		47,885		43,742

Total net lease cost	$	16,831	$	17,089	$	54,926	$	50,864

As of December 31, 2023, the maturities of lease liabilities were as follows:


(In thousands)
Year Ending March 31,	Operating Leases		Finance Lease		Total
2024 (remaining three months ending March 31, 2024)	$	1,806	$	731	$	2,537
2025	4,834		1,509		6,343
2026	2,348		96		2,444
2027	1,916		80		1,996
2028	1,437		—		1,437
Thereafter	265		—		265
Total undiscounted lease payments	12,606		2,416		15,022
Less amount of lease payments representing interest	(818)		(33)		(851)
Total present value of lease payments	$	11,788	$	2,383	$	14,171

The weighted average remaining lease term and weighted average discount rate were as follows:


		December 31, 2023
Weighted average remaining lease term (years)
	Operating leases	2.95
	Finance leases	1.03
Weighted average discount rate
	Operating leases	3.80	%
	Finance leases	2.93	%

Leases

We lease real estate and equipment for use in our operations.

The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Finance lease cost:
Amortization of right-of-use assets	$	665	$	665	$	1,994	$	1,994
Interest on lease liabilities	20		41		74		136
Operating lease cost	1,624		1,621		4,872		4,872
Short term lease cost	34		35		101		120
Variable lease cost	14,488		14,727		47,885		43,742

Total net lease cost	$	16,831	$	17,089	$	54,926	$	50,864

As of December 31, 2023, the maturities of lease liabilities were as follows:


(In thousands)
Year Ending March 31,	Operating Leases		Finance Lease		Total
2024 (remaining three months ending March 31, 2024)	$	1,806	$	731	$	2,537
2025	4,834		1,509		6,343
2026	2,348		96		2,444
2027	1,916		80		1,996
2028	1,437		—		1,437
Thereafter	265		—		265
Total undiscounted lease payments	12,606		2,416		15,022
Less amount of lease payments representing interest	(818)		(33)		(851)
Total present value of lease payments	$	11,788	$	2,383	$	14,171

The weighted average remaining lease term and weighted average discount rate were as follows:


		December 31, 2023
Weighted average remaining lease term (years)
	Operating leases	2.95
	Finance leases	1.03
Weighted average discount rate
	Operating leases	3.80	%
	Finance leases	2.93	%

Other Accrued Liabilities

9 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Other Accrued Liabilities

Other accrued liabilities consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Accrued marketing costs	$	29,648	$	30,471
Accrued compensation costs	9,940		14,292
Accrued broker commissions	1,888		1,767
Income taxes payable	5,953		10,645
Accrued professional fees	5,100		4,254

Accrued production costs	4,568		5,700



Other accrued liabilities	7,966		5,395
	$	65,063	$	72,524

Long-Term Debt

9 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Long-Term Debt

Long-term debt consists of the following, as of the dates indicated:


(In thousands, except percentages)	December 31, 2023		March 31, 2023

2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031.	$	600,000	$	600,000
2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028.	400,000		400,000

2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at December 31, 2023), due on July 1, 2028.	210,000		360,000



Long-term debt	1,210,000		1,360,000
Less: unamortized debt costs	(10,660)		(14,212)

Long-term debt, net	$	1,199,340	$	1,345,788

At December 31, 2023, we had no balance outstanding on the 2012 ABL Revolver and a borrowing capacity of $168.9 million.

On April 4, 2023, we entered into ABL Amendment No. 8. ABL Amendment No. 8 provides for the replacement of LIBOR with SOFR as our reference rate for the 2012 ABL Revolver.


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ending March 31, 2024)	$	—
2025	—
2026	—
2027	—
2028	400,000
Thereafter	810,000
	$	1,210,000

Fair Value Measurements

9 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant.


	December 31, 2023		March 31, 2023
(In thousands)	Carrying Value	Fair Value	Carrying Value	Fair Value
2019 Senior Notes	400,000	391,000	400,000	383,500
2021 Senior Notes	600,000	523,500	600,000	510,750


2012 Term B-5 Loans	210,000	210,263	360,000	359,550

At December 31, 2023 and March 31, 2023, we did not have any assets or liabilities measured in Level 1 or 3.

Stockholders' Equity

9 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity

During the three and nine months ended December 31, 2023 and 2022, we repurchased shares of our common stock and recorded them as treasury stock. Our share repurchases consisted of the following:


	Three Months Ended December 31,				Nine Months Ended December 31,
	2023		2022		2023	2022
Shares repurchased pursuant to the provisions of the various employee restricted stock awards:
Number of shares	—		303		88,953	99,522
Average price per share	$	—	$50.63		$61.92	$54.92
Total amount repurchased	$	—	$0.02 million		$5.5 million	$5.5 million

Shares repurchased in conjunction with our share repurchase program:
Number of shares	—		—		426,479	914,236
Average price per share	$	—	$	—	$58.62	$54.69
Total amount repurchased	$	—	$	—	$25.0 million	$50.0 million

Accumulated Other Comprehensive Loss

9 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consisted of the following at December 31, 2023 and March 31, 2023:


(In thousands)	December 31, 2023		March 31, 2023
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(29,245)	$	(32,280)

Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively	716		716
Accumulated other comprehensive loss, net of tax	$	(28,529)	$	(31,564)

As of December 31, 2023 and March 31, 2023, no amounts were reclassified from accumulated other comprehensive loss into earnings.

Earnings Per Share

9 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator
Net income	$	53,046	$	51,951	$	159,881	$	158,246

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	49,740		49,693		49,731		49,919
Dilutive effect of unvested restricted stock units and options issued to employees and directors	385		493		403		473
Denominator for diluted earnings per share	50,125		50,186		50,134		50,392

Earnings per Common Share:
Basic earnings per share	$	1.07	$	1.05	$	3.21	$	3.17

Diluted earnings per share	$	1.06	$	1.04	$	3.19	$	3.14

Stock-Based Compensation

9 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

The following table provides information regarding our stock-based compensation:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Pre-tax stock-based compensation costs charged against income	$	2,449	$	2,433	$	10,283	$	9,756
Income tax benefit recognized on compensation costs	$	241	$	49	$	910	$	924
Total fair value of options and RSUs vested during the period	$	—	$	63	$	12,213	$	10,352
Cash received from the exercise of stock options	$	1,635	$	5,684	$	10,818	$	7,173
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$	351	$	731	$	1,490	$	3,626

At December 31, 2023, there were 1.9 million shares available for issuance under the 2020 Plan.

Restricted Stock Units

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:


RSUs	Shares (in thousands)	Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2022
Unvested at March 31, 2022	440.9	$	38.45
Granted	151.0	55.03
Incremental performance shares	42.4	—
Vested	(223.4)	32.09
Forfeited	(1.9)	49.51
Unvested at December 31, 2022	409.0	47.17
Vested at December 31, 2022	108.5	36.54

Nine Months Ended December 31, 2023
Unvested at March 31, 2023	409.0	$	47.17
Granted	157.1	62.06
Incremental performance shares	41.4	—
Vested	(205.0)	43.17
Forfeited	(10.6)	52.68
Unvested at December 31, 2023	391.9	54.43
Vested at December 31, 2023	110.2	38.77

Options

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:


	Nine Months Ended December 31,
	2023		2022
Expected volatility	30.2% - 31.6%		30.8% - 30.9%
Expected dividends	$	—	$	—
Expected term in years	6.0 to 7.0		6.0 to 7.0
Risk-free rate	3.6% to 4.1%		2.8% to 2.9%
Weighted average grant date fair value of options granted	$	23.79	$	20.10

A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:


Options	Shares (in thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2022
Outstanding at March 31, 2022	1,100.9	$	40.62
Granted	197.6	54.48
Exercised	(200.2)	35.82
Forfeited	(10.3)	49.53
Expired	(0.8)	44.33
Outstanding at December 31, 2022	1,087.2	43.94		6.7	$	20,289
Vested at December 31, 2022	670.5	41.18		5.4	$	14,360

Nine Months Ended December 31, 2023
Outstanding at March 31, 2023	1,081.0	$	43.96
Granted	131.1	61.81
Exercised	(268.9)	40.23
Forfeited	(41.0)	54.15
Expired	(2.8)	54.47
Outstanding at December 31, 2023	899.4	47.18		6.2	$	12,703
Vested at December 31, 2023	606.2	43.23		5.0	$	10,903

The aggregate intrinsic value of options exercised during the nine months ended December 31, 2023 was $5.4 million.

Income Taxes	9 Months Ended
Income Taxes	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 23.8% and 23.7% for the three months ended December 31, 2023 and 2022, respectively. The effective tax rates used in the calculation of income taxes were 23.4% and 23.0% for the nine months ended December 31, 2023 and 2022, respectively. The increase in the effective tax rate for the three months ended December 31, 2023, compared to the three months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation. The increase in the effective tax rate for the nine months ended December 31, 2023, compared to the nine months ended December 31, 2022, was due to discrete items primarily pertaining to stock-based compensation and state tax rate legislative changes.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.

Concentrations of Risk	9 Months Ended
Concentrations of Risk	Dec. 31, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels. During the three and nine months ended December 31, 2023, approximately 37.0% and 37.8%, respectively, of our gross revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2022, approximately 36.9% and 38.7%, respectively, of our gross revenues were derived from our five top selling brands. Walmart accounted for approximately 19.0% and 19.6%, respectively, of our gross revenues for the three and nine months ended December 31, 2023. Walmart accounted for approximately 19.9% and 19.8%, respectively, of our gross revenues for the three and nine months ended December 31, 2022. Amazon accounted for approximately 10.7% and 10.4%, respectively, of gross revenues for the three and nine months ended December 31, 2023. Our product distribution in the United States is managed by a third party through one primary distribution center in Clayton, Indiana. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia, which manufactures many of the Summer's Eve and Fleet products. A natural disaster, such as tornado, earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. In addition, a serious disruption caused by performance or contractual issues with our third-party distribution manager or labor shortages or public health emergencies at our distribution center or manufacturing facility could materially impact our product distribution. Any disruption could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution center, the third-party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At December 31, 2023, we had relationships with 129 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 72.1% of gross sales for the nine months ended December 31, 2023. At December 31, 2022, we had relationships with 133 third-party manufacturers. Of those, we had long-term contracts with 27 manufacturers that produced items that accounted for approximately 70.5% of gross sales for the nine months ended December 31, 2022. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

9 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Business Segments

The tables below summarize information about our reportable segments.


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,565	$	46,176	$	282,741
Cost of sales	106,090		18,713		124,803
Gross profit	130,475		27,463		157,938
Advertising and marketing	33,917		5,549		39,466
Contribution margin	$	96,558	$	21,914	$	118,472
Other operating expenses					31,640
Operating income					$	86,832
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	727,131	$	121,235	$	848,366
Cost of sales	323,632		52,103		375,735
Gross profit	403,499		69,132		472,631
Advertising and marketing	100,707		15,092		115,799
Contribution margin	$	302,792	$	54,040	$	356,832
Other operating expenses					96,556
Operating income					$	260,276
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,884	$	38,640	$	275,524
Cost of sales	110,554		14,568		125,122
Gross profit	126,330		24,072		150,402
Advertising and marketing	24,831		5,592		30,423
Contribution margin	$	101,499	$	18,480	$	119,979
Other operating expenses					32,795
Operating income					$	87,184
* Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	731,456	$	110,400	$	841,856
Cost of sales	327,008		43,318		370,326
Gross profit	404,448		67,082		471,530
Advertising and marketing	99,559		14,634		114,193
Contribution margin	$	304,889	$	52,448	$	357,337
Other operating expenses					98,755
Operating income					$	258,582
* Intersegment revenues of $2.8 million were eliminated from the North American OTC Healthcare segment.

The tables below summarize information about our segment revenues from similar product groups.


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	28,680	$	1,586	$	30,266
Cough & Cold	27,359		5,814		33,173
Women's Health	53,076		5,190		58,266
Gastrointestinal	38,919		22,707		61,626
Eye & Ear Care	38,503		6,569		45,072
Dermatologicals	26,603		1,165		27,768
Oral Care	20,362		3,100		23,462
Other OTC	3,063		45		3,108

Total segment revenues	$	236,565	$	46,176	$	282,741


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	85,838	$	3,814	$	89,652
Cough & Cold	73,703		19,129		92,832
Women's Health	163,031		17,218		180,249
Gastrointestinal	122,303		49,678		171,981
Eye & Ear Care	117,719		17,715		135,434
Dermatologicals	94,299		3,972		98,271
Oral Care	61,400		9,591		70,991
Other OTC	8,838		118		8,956

Total segment revenues	$	727,131	$	121,235	$	848,366


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	29,396	$	648	$	30,044
Cough & Cold	31,246		6,336		37,582
Women's Health	53,918		4,138		58,056
Gastrointestinal	38,194		18,555		56,749
Eye & Ear Care	32,653		5,229		37,882
Dermatologicals	27,223		978		28,201
Oral Care	21,371		2,738		24,109
Other OTC	2,883		18		2,901

Total segment revenues	$	236,884	$	38,640	$	275,524


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	89,943	$	1,642	$	91,585
Cough & Cold	76,896		19,775		96,671
Women's Health	174,481		13,750		188,231
Gastrointestinal	119,533		48,619		168,152
Eye & Ear Care	109,225		14,699		123,924
Dermatologicals	89,550		2,886		92,436
Oral Care	63,597		8,988		72,585
Other OTC	8,231		41		8,272

Total segment revenues	$	731,456	$	110,400	$	841,856

Business and Basis of Presentation (Policies)	9 Months Ended
Business and Basis of Presentation (Policies)	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2024) mean our fiscal year ending or ended on March 31st of that year. Operating results for the nine months ended December 31, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2024. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires entities to apply Topic 606 to recognize and measure contract assets and liabilities in a business combination. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We adopted this standard effective April 1, 2023. The impact of the adoption of this new standard will depend on the magnitude of future acquisitions. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and also issued subsequent amendments to the initial guidance (collectively, "Topic 848"). In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extends the period of time preparers can utilize the reference rate reform relief guidance in Topic 848. Topic 848 provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. On April 4, 2023, we entered into Amendment No. 8 ("ABL Amendment No. 8") to the Company's asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver"). ABL Amendment No. 8 provides for the replacement of LIBOR with Secured Overnight Financing Rate ("SOFR") as our reference rate. On June 12, 2023, we entered into Amendment No. 7 ("Term Loan Amendment No. 7") to the Company’s term loan originally entered into on January 31, 2012 (the “2012 Term Loan”), effective July 1, 2023. Term Loan Amendment No. 7 provides for the replacement of LIBOR with SOFR as our reference rate. Effective July 1, 2023, we have transitioned all discontinued reference rates to SOFR. The adoption of Topic 848 did not have a material impact on our Consolidated Financial Statements. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update require that entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update also require disclosure, on an annual basis, of income taxes paid, disaggregated by federal, state and foreign taxes and disaggregated by individual jurisdictions in which income taxes paid are equal to or greater than five percent of total income taxes paid. In addition, the amendments in this update also require that income (or loss) before income taxes be disaggregated between domestic and foreign and income tax expense (or benefit) be disaggregated by federal, state and foreign. This ASU is effective for annual periods beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update intend to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. This ASU requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, the addition of a category for other segment items by reportable segment, that all annual segment disclosures be disclosed in interim periods, and other related segment disclosures. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating the impact that this ASU may have on our consolidated financial statement disclosures.

Inventories (Tables)

9 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Components of Inventories
Packaging and raw materials	$	22,093	$	20,634
Work in process	555		220
Finished goods	125,989		141,267

Inventories	$	148,637	$	162,121

Goodwill (Tables)

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of the Activity Affecting Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:


(In thousands)		North American OTC Healthcare		International OTC Healthcare		Consolidated
Balance - March 31, 2023
	Goodwill	$	711,452	$	30,204	$	741,656
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - March 31, 2023		498,936		28,617		527,553




	Effects of foreign currency exchange rates	—		325		325
Balance - December 31, 2023
	Goodwill	711,452		30,529		741,981
	Accumulated impairment loss	(212,516)		(1,587)		(214,103)
Balance - December 31, 2023		$	498,936	$	28,942	$	527,878

Intangible Assets, net (Tables)

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Reconciliation of the Activity Affecting Finite-Lived Intangible Assets

A reconciliation of the activity affecting intangible assets, net is as follows:


(In thousands)	Indefinite- Lived Trademarks		Finite-Lived Trademarks and Customer Relationships		Totals
Gross Carrying Amounts
Balance — March 31, 2023	$	2,168,902	$	411,118	$	2,580,020




Effects of foreign currency exchange rates	1,223		334		1,557
Balance — December 31, 2023	$	2,170,125	$	411,452	$	2,581,577

Accumulated Amortization
Balance — March 31, 2023	$	—	$	238,127	$	238,127

Additions	—		14,842		14,842

Effects of foreign currency exchange rates	—		79		79
Balance — December 31, 2023	$	—	$	253,048	$	253,048

Intangible assets, net - December 31, 2023	$	2,170,125	$	158,404	$	2,328,529

Reconciliation of the Activity Affecting Indefinite-Lived Intangible Assets

A reconciliation of the activity affecting intangible assets, net is as follows:


(In thousands)	Indefinite- Lived Trademarks		Finite-Lived Trademarks and Customer Relationships		Totals
Gross Carrying Amounts
Balance — March 31, 2023	$	2,168,902	$	411,118	$	2,580,020




Effects of foreign currency exchange rates	1,223		334		1,557
Balance — December 31, 2023	$	2,170,125	$	411,452	$	2,581,577

Accumulated Amortization
Balance — March 31, 2023	$	—	$	238,127	$	238,127

Additions	—		14,842		14,842

Effects of foreign currency exchange rates	—		79		79
Balance — December 31, 2023	$	—	$	253,048	$	253,048

Intangible assets, net - December 31, 2023	$	2,170,125	$	158,404	$	2,328,529

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ended March 31, 2024)	$	4,947
2025	18,115
2026	16,165
2027	14,574
2028	12,237
Thereafter	92,366
	$	158,404

Leases (Tables)

9 Months Ended

Dec. 31, 2023

Leases [Abstract]

Components of Lease Expense

The components of lease expense for the three and nine months ended December 31, 2023 and 2022 were as follows:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Finance lease cost:
Amortization of right-of-use assets	$	665	$	665	$	1,994	$	1,994
Interest on lease liabilities	20		41		74		136
Operating lease cost	1,624		1,621		4,872		4,872
Short term lease cost	34		35		101		120
Variable lease cost	14,488		14,727		47,885		43,742

Total net lease cost	$	16,831	$	17,089	$	54,926	$	50,864

The weighted average remaining lease term and weighted average discount rate were as follows:


		December 31, 2023
Weighted average remaining lease term (years)
	Operating leases	2.95
	Finance leases	1.03
Weighted average discount rate
	Operating leases	3.80	%
	Finance leases	2.93	%

Maturities of Operating Leases

As of December 31, 2023, the maturities of lease liabilities were as follows:


(In thousands)
Year Ending March 31,	Operating Leases		Finance Lease		Total
2024 (remaining three months ending March 31, 2024)	$	1,806	$	731	$	2,537
2025	4,834		1,509		6,343
2026	2,348		96		2,444
2027	1,916		80		1,996
2028	1,437		—		1,437
Thereafter	265		—		265
Total undiscounted lease payments	12,606		2,416		15,022
Less amount of lease payments representing interest	(818)		(33)		(851)
Total present value of lease payments	$	11,788	$	2,383	$	14,171

Maturities of Finance Leases

As of December 31, 2023, the maturities of lease liabilities were as follows:


(In thousands)
Year Ending March 31,	Operating Leases		Finance Lease		Total
2024 (remaining three months ending March 31, 2024)	$	1,806	$	731	$	2,537
2025	4,834		1,509		6,343
2026	2,348		96		2,444
2027	1,916		80		1,996
2028	1,437		—		1,437
Thereafter	265		—		265
Total undiscounted lease payments	12,606		2,416		15,022
Less amount of lease payments representing interest	(818)		(33)		(851)
Total present value of lease payments	$	11,788	$	2,383	$	14,171

Other Accrued Liabilities (Tables)

9 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Other Accrued Liabilities

Other accrued liabilities consist of the following:


(In thousands)	December 31, 2023		March 31, 2023
Accrued marketing costs	$	29,648	$	30,471
Accrued compensation costs	9,940		14,292
Accrued broker commissions	1,888		1,767
Income taxes payable	5,953		10,645
Accrued professional fees	5,100		4,254

Accrued production costs	4,568		5,700



Other accrued liabilities	7,966		5,395
	$	65,063	$	72,524

Long-Term Debt (Tables)

9 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:


(In thousands, except percentages)	December 31, 2023		March 31, 2023

2021 Senior Notes bearing interest at 3.750%, with interest payable on April 1 and October 1 of each year. The 2021 Senior Notes mature on April 1, 2031.	$	600,000	$	600,000
2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028.	400,000		400,000

2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.50%, or an alternate base rate plus a margin of 1.00% per annum (at March 31, 2023) and SOFR plus a margin of 2.00% plus a credit spread adjustment (at December 31, 2023), due on July 1, 2028.	210,000		360,000



Long-term debt	1,210,000		1,360,000
Less: unamortized debt costs	(10,660)		(14,212)

Long-term debt, net	$	1,199,340	$	1,345,788

Aggregate Future Principal Payments


(In thousands)
Year Ending March 31,	Amount
2024 (remaining three months ending March 31, 2024)	$	—
2025	—
2026	—
2027	—
2028	400,000
Thereafter	810,000
	$	1,210,000

Fair Value Measurements (Tables)

9 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Summary of Carry Amounts and Fair Value Measurements

The summary below details the carrying amounts and estimated fair values of these instruments at December 31, 2023 and March 31, 2023.


	December 31, 2023		March 31, 2023
(In thousands)	Carrying Value	Fair Value	Carrying Value	Fair Value
2019 Senior Notes	400,000	391,000	400,000	383,500
2021 Senior Notes	600,000	523,500	600,000	510,750


2012 Term B-5 Loans	210,000	210,263	360,000	359,550

Stockholders' Equity (Tables)

9 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Class of Treasury Stock

Our share repurchases consisted of the following:


	Three Months Ended December 31,				Nine Months Ended December 31,
	2023		2022		2023	2022
Shares repurchased pursuant to the provisions of the various employee restricted stock awards:
Number of shares	—		303		88,953	99,522
Average price per share	$	—	$50.63		$61.92	$54.92
Total amount repurchased	$	—	$0.02 million		$5.5 million	$5.5 million

Shares repurchased in conjunction with our share repurchase program:
Number of shares	—		—		426,479	914,236
Average price per share	$	—	$	—	$58.62	$54.69
Total amount repurchased	$	—	$	—	$25.0 million	$50.0 million

Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consisted of the following at December 31, 2023 and March 31, 2023:


(In thousands)	December 31, 2023		March 31, 2023
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(29,245)	$	(32,280)

Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively	716		716
Accumulated other comprehensive loss, net of tax	$	(28,529)	$	(31,564)

Earnings Per Share (Tables)

9 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator
Net income	$	53,046	$	51,951	$	159,881	$	158,246

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	49,740		49,693		49,731		49,919
Dilutive effect of unvested restricted stock units and options issued to employees and directors	385		493		403		473
Denominator for diluted earnings per share	50,125		50,186		50,134		50,392

Earnings per Common Share:
Basic earnings per share	$	1.07	$	1.05	$	3.21	$	3.17

Diluted earnings per share	$	1.06	$	1.04	$	3.19	$	3.14

Stock-Based Compensation (Tables)

9 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Compensation Expense Information

The following table provides information regarding our stock-based compensation:


	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2023		2022		2023		2022
Pre-tax stock-based compensation costs charged against income	$	2,449	$	2,433	$	10,283	$	9,756
Income tax benefit recognized on compensation costs	$	241	$	49	$	910	$	924
Total fair value of options and RSUs vested during the period	$	—	$	63	$	12,213	$	10,352
Cash received from the exercise of stock options	$	1,635	$	5,684	$	10,818	$	7,173
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$	351	$	731	$	1,490	$	3,626

Summary of Restricted Shares

A summary of the RSUs granted under the 2005 Plan and the 2020 Plan is presented below:


RSUs	Shares (in thousands)	Weighted Average Grant-Date Fair Value
Nine Months Ended December 31, 2022
Unvested at March 31, 2022	440.9	$	38.45
Granted	151.0	55.03
Incremental performance shares	42.4	—
Vested	(223.4)	32.09
Forfeited	(1.9)	49.51
Unvested at December 31, 2022	409.0	47.17
Vested at December 31, 2022	108.5	36.54

Nine Months Ended December 31, 2023
Unvested at March 31, 2023	409.0	$	47.17
Granted	157.1	62.06
Incremental performance shares	41.4	—
Vested	(205.0)	43.17
Forfeited	(10.6)	52.68
Unvested at December 31, 2023	391.9	54.43
Vested at December 31, 2023	110.2	38.77

Fair Value of Options Granted

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions presented below:


	Nine Months Ended December 31,
	2023		2022
Expected volatility	30.2% - 31.6%		30.8% - 30.9%
Expected dividends	$	—	$	—
Expected term in years	6.0 to 7.0		6.0 to 7.0
Risk-free rate	3.6% to 4.1%		2.8% to 2.9%
Weighted average grant date fair value of options granted	$	23.79	$	20.10

Stock Option Activity

A summary of option activity under the 2005 Plan and the 2020 Plan is as follows:


Options	Shares (in thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Nine Months Ended December 31, 2022
Outstanding at March 31, 2022	1,100.9	$	40.62
Granted	197.6	54.48
Exercised	(200.2)	35.82
Forfeited	(10.3)	49.53
Expired	(0.8)	44.33
Outstanding at December 31, 2022	1,087.2	43.94		6.7	$	20,289
Vested at December 31, 2022	670.5	41.18		5.4	$	14,360

Nine Months Ended December 31, 2023
Outstanding at March 31, 2023	1,081.0	$	43.96
Granted	131.1	61.81
Exercised	(268.9)	40.23
Forfeited	(41.0)	54.15
Expired	(2.8)	54.47
Outstanding at December 31, 2023	899.4	47.18		6.2	$	12,703
Vested at December 31, 2023	606.2	43.23		5.0	$	10,903

Business Segments (Tables)

9 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Operating and Reportable Segments

The tables below summarize information about our reportable segments.


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,565	$	46,176	$	282,741
Cost of sales	106,090		18,713		124,803
Gross profit	130,475		27,463		157,938
Advertising and marketing	33,917		5,549		39,466
Contribution margin	$	96,558	$	21,914	$	118,472
Other operating expenses					31,640
Operating income					$	86,832
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	727,131	$	121,235	$	848,366
Cost of sales	323,632		52,103		375,735
Gross profit	403,499		69,132		472,631
Advertising and marketing	100,707		15,092		115,799
Contribution margin	$	302,792	$	54,040	$	356,832
Other operating expenses					96,556
Operating income					$	260,276
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	236,884	$	38,640	$	275,524
Cost of sales	110,554		14,568		125,122
Gross profit	126,330		24,072		150,402
Advertising and marketing	24,831		5,592		30,423
Contribution margin	$	101,499	$	18,480	$	119,979
Other operating expenses					32,795
Operating income					$	87,184
* Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Total segment revenues*	$	731,456	$	110,400	$	841,856
Cost of sales	327,008		43,318		370,326
Gross profit	404,448		67,082		471,530
Advertising and marketing	99,559		14,634		114,193
Contribution margin	$	304,889	$	52,448	$	357,337
Other operating expenses					98,755
Operating income					$	258,582
* Intersegment revenues of $2.8 million were eliminated from the North American OTC Healthcare segment.

Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.


	Three Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	28,680	$	1,586	$	30,266
Cough & Cold	27,359		5,814		33,173
Women's Health	53,076		5,190		58,266
Gastrointestinal	38,919		22,707		61,626
Eye & Ear Care	38,503		6,569		45,072
Dermatologicals	26,603		1,165		27,768
Oral Care	20,362		3,100		23,462
Other OTC	3,063		45		3,108

Total segment revenues	$	236,565	$	46,176	$	282,741


	Nine Months Ended December 31, 2023
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	85,838	$	3,814	$	89,652
Cough & Cold	73,703		19,129		92,832
Women's Health	163,031		17,218		180,249
Gastrointestinal	122,303		49,678		171,981
Eye & Ear Care	117,719		17,715		135,434
Dermatologicals	94,299		3,972		98,271
Oral Care	61,400		9,591		70,991
Other OTC	8,838		118		8,956

Total segment revenues	$	727,131	$	121,235	$	848,366


	Three Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	29,396	$	648	$	30,044
Cough & Cold	31,246		6,336		37,582
Women's Health	53,918		4,138		58,056
Gastrointestinal	38,194		18,555		56,749
Eye & Ear Care	32,653		5,229		37,882
Dermatologicals	27,223		978		28,201
Oral Care	21,371		2,738		24,109
Other OTC	2,883		18		2,901

Total segment revenues	$	236,884	$	38,640	$	275,524


	Nine Months Ended December 31, 2022
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Consolidated
Analgesics	$	89,943	$	1,642	$	91,585
Cough & Cold	76,896		19,775		96,671
Women's Health	174,481		13,750		188,231
Gastrointestinal	119,533		48,619		168,152
Eye & Ear Care	109,225		14,699		123,924
Dermatologicals	89,550		2,886		92,436
Oral Care	63,597		8,988		72,585
Other OTC	8,231		41		8,272

Total segment revenues	$	731,456	$	110,400	$	841,856

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 22,093	$ 20,634
Work in process	555	220
Finished goods	125,989	141,267
Inventories	$ 148,637	$ 162,121

Inventories - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 5.8	$ 5.8

Goodwill - Schedule of Changes (Details) $ in Thousands	9 Months Ended
Goodwill - Schedule of Changes (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 741,656
Accumulated impairment loss, beginning	(214,103)
Goodwill, net, beginning	527,553
Effects of foreign currency exchange rates	325
Goodwill, gross, ending	741,981
Accumulated impairment loss, ending	(214,103)
Goodwill, net, ending	527,878
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	711,452
Accumulated impairment loss, beginning	(212,516)
Goodwill, net, beginning	498,936
Effects of foreign currency exchange rates	0
Goodwill, gross, ending	711,452
Accumulated impairment loss, ending	(212,516)
Goodwill, net, ending	498,936
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	30,204
Accumulated impairment loss, beginning	(1,587)
Goodwill, net, beginning	28,617
Effects of foreign currency exchange rates	325
Goodwill, gross, ending	30,529
Accumulated impairment loss, ending	(1,587)
Goodwill, net, ending	$ 28,942

Goodwill - Narrative (Details) $ in Millions	12 Months Ended
Goodwill - Narrative (Details) $ in Millions	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 48.8

Intangible Assets, net - Activity Affecting Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			$ 2,580,020
Totals, effects of foreign currency exchange rate			1,557
Totals, gross, ending balance	$ 2,581,577		2,581,577
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions	4,900	$ 5,600	14,842	$ 16,900
Accumulated amortization, effects of foreign exchange rates			79
Accumulated amortization, ending balance	253,048		253,048
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	158,404		158,404
Intangible Assets, Net [Abstract]
Intangible assets, net	2,328,529		2,328,529		$ 2,341,893
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance			411,118
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			334
Finite-lived trademarks and customer relationships, ending balance	411,452		411,452
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			238,127
Accumulated amortization, additions			14,842
Accumulated amortization, effects of foreign exchange rates			79
Accumulated amortization, ending balance	253,048		253,048
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, net	158,404		158,404
Indefinite-Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			2,168,902
Indefinite lived trademarks, effects of foreign currency exchange rate			1,223
Indefinite-lived trademarks, ending balance	$ 2,170,125		$ 2,170,125

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 4,900	$ 5,600	$ 14,842	$ 16,900
Impairment of intangible assets					$ 321,400
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years		10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years		25 years

Intangible Assets, net - Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remaining three months ended March 31, 2024)	$ 4,947
2025	18,115
2026	16,165
2027	14,574
2028	12,237
Thereafter	92,366
Finite-lived intangible assets, net	$ 158,404

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Leases - Lease Cost (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Finance lease cost, amortization of right-of-use assets	$ 665	$ 665	$ 1,994	$ 1,994
Finance lease cost, interest on lease liabilities	20	41	74	136
Operating lease cost	1,624	1,621	4,872	4,872
Short term lease cost	34	35	101	120
Variable lease cost	14,488	14,727	47,885	43,742
Total net lease cost	$ 16,831	$ 17,089	$ 54,926	$ 50,864

Leases - Lease Maturities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Operating Leases
2024 (remaining three months ending March 31, 2024)	$ 1,806
2025	4,834
2026	2,348
2027	1,916
2028	1,437
Thereafter	265
Total undiscounted lease payments	12,606
Less amount of lease payments representing interest	(818)
Total present value of lease payments	11,788
Finance Lease
2024 (remaining three months ending March 31, 2024)	731
2025	1,509
2026	96
2027	80
2028	0
Thereafter	0
Total undiscounted lease payments	2,416
Less amount of lease payments representing interest	(33)
Total present value of lease payments	2,383
Total
2024 (remaining three months ending March 31, 2024)	2,537
2025	6,343
2026	2,444
2027	1,996
2028	1,437
Thereafter	265
Total undiscounted lease payments	15,022
Less amount of lease payments representing interest	(851)
Total present value of lease payments	$ 14,171

Leases - Additional Information (Details)	Dec. 31, 2023
Weighted average remaining lease term (years)
Operating leases	2 years 11 months 12 days
Finance leases	1 year 10 days
Weighted average discount rate
Operating leases	3.80%
Finance leases	2.93%

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued marketing costs	$ 29,648	$ 30,471
Accrued compensation costs	9,940	14,292
Accrued broker commissions	1,888	1,767
Income taxes payable	5,953	10,645
Accrued professional fees	5,100	4,254
Accrued production costs	4,568	5,700
Other accrued liabilities	7,966	5,395
Total other accrued liabilities	$ 65,063	$ 72,524

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2023
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,210,000
Long-term debt, net	1,210,000	$ 1,360,000
Less: unamortized debt costs	(10,660)	(14,212)
Long-term debt, net	$ 1,199,340	1,345,788
Senior Notes \| 2021 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.75%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes \| 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.125%
Total long-term debt (including current portion)	$ 400,000	400,000
Term Loans \| 2012 Term B-5 Loans
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 210,000	$ 360,000
Term Loans \| 2012 Term B-5 Loans \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2.00%
Debt instrument, variable rate, minimum		0.50%
Term Loans \| 2012 Term B-5 Loans \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Term Loans \| 2012 Term B-5 Loans \| SOFR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.00%

Long-Term Debt - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 08, 2023	Dec. 07, 2023
Debt Instrument [Line Items]
Long-term debt outstanding	$ 1,210,000
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt outstanding	0
Borrowing capacity	$ 168,900	$ 200,000	$ 175,000

Long-Term Debt - Maturities of Long-term Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Aggregate Future Principal Payments
2024 (remaining three months ending March 31, 2024)	$ 0
2025	0
2026	0
2027	0
2028	400,000
Thereafter	810,000
Total long-term debt (including current portion)	$ 1,210,000

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Senior Notes \| 2019 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 400,000	$ 400,000
Senior Notes \| 2021 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	600,000	600,000
Term Loans \| 2012 Term B-5 Loans \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	210,000	360,000
Fair Value, Measurements, Recurring \| Senior Notes \| 2019 Senior Notes \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	391,000	383,500
Fair Value, Measurements, Recurring \| Senior Notes \| 2021 Senior Notes \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	523,500	510,750
Fair Value, Measurements, Recurring \| Term Loans \| 2012 Term B-5 Loans \| Fair Value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 210,263	$ 359,550

Stockholders' Equity - Narrative (Details)	9 Months Ended
Stockholders' Equity - Narrative (Details)	Dec. 31, 2023 USD ($) vote $ / shares shares	May 02, 2023 USD ($)	Mar. 31, 2023 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized (in shares) \| shares	250,000,000		250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) \| shares	5,000,000		5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01		$ 0.01
Voting rights, number of votes per common share owned \| vote	1
Dividends declared on common stock \| $	$ 0
Stock repurchase program, authorized amount \| $		$ 25,000,000

Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Total amount repurchased		$ 16	$ 30,524	$ 55,466
Share Repurchase Program
Class of Stock [Line Items]
Number of shares (in shares)	0	0	426,479	914,236
Average price per share (in USD per share)	$ 0	$ 0	$ 58.62	$ 54.69
Total amount repurchased	$ 0	$ 0	$ 25,000	$ 50,000
Restricted Shares
Class of Stock [Line Items]
Number of shares (in shares)	0	303	88,953	99,522
Average price per share (in USD per share)	$ 0	$ 50.63	$ 61.92	$ 54.92
Total amount repurchased	$ 0	$ 20	$ 5,500	$ 5,500

Accumulated Other Comprehensive Loss - Components of AOCL (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,600,577	$ 1,535,959	$ 1,447,084	$ 1,686,863	$ 1,619,841	$ 1,577,611
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(28,529)	$ (35,994)	(31,564)	$ (29,489)	$ (36,459)	$ (19,032)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(29,245)		(32,280)
Unrecognized net gain on pension plans, net of tax of $(214) and $(214), respectively
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	716		716
Unrecognized net gain on pension plan, tax	$ (214)		$ (214)

Accumulated Other Comprehensive Loss - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Reclassification from accumulated other comprehensive loss into earnings	$ 0	$ 0

Earnings Per Share - Computation of Basis and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Numerator
Net income	$ 53,046	$ 51,951	$ 159,881	$ 158,246
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	49,740	49,693	49,731	49,919
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	385	493	403	473
Denominator for diluted earnings per share (in shares)	50,125	50,186	50,134	50,392
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 1.07	$ 1.05	$ 3.21	$ 3.17
Diluted earnings per share (in USD per share)	$ 1.06	$ 1.04	$ 3.19	$ 3.14

Earnings Per Share - Antidilutive Securities (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0.3	0.2	0.3	0.4

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Jun. 30, 2014	Dec. 31, 2023	Jun. 23, 2020	May 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 3.1
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		1 year 10 months 24 days
Shares available for issuance under the Plan (in shares)		1,900,000
Options exercised, aggregate intrinsic value		$ 5.4
Restricted Stock Units (RSUs) & Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to nonvested awards		$ 12.9
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition (years)		1 year 8 months 12 days
Long-term Equity Incentive Plan, 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)				5,000,000
Number of additional shares authorized (in shares)	1,800,000
Long-term Incentive Plan, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			2,827,210
Number of new shares for future issuance under 2020 long-term incentive plans (in shares)			2,000,000
Number of unissued shares reserved for 2020 long-term incentive plans (in shares)			827,210

Stock-Based Compensation - Stock Based Compensation Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Pre-tax stock-based compensation costs charged against income	$ 2,449	$ 2,433	$ 10,283	$ 9,756
Income tax benefit recognized on compensation costs	241	49	910	924
Total fair value of options and RSUs vested during the period	0	63	12,213	10,352
Cash received from the exercise of stock options	1,635	5,684	10,818	7,173
Tax benefits realized from tax deductions resulting from RSU issuances and stock option exercises	$ 351	$ 731	$ 1,490	$ 3,626

Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Shares
Outstanding, beginning of period (in shares)	409,000.0	440,900
Granted (in shares)	157,100	151,000.0
Incremental performance shares (in shares)	41,400	42,400
Vested (in shares)	(205,000.0)	(223,400)
Forfeited (in shares)	(10,600)	(1,900)
Outstanding, end of period (in shares)	391,900	409,000.0
Vested, end of period (in shares)	110,200	108,500
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 47.17	$ 38.45
Granted, weighted-average grant-date fair value (in USD per share)	62.06	55.03
Vested, weighted-average grant-date fair value (in USD per share)	43.17	32.09
Forfeited, weighted-average grant-date fair value (in USD per share)	52.68	49.51
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	54.43	47.17
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 38.77	$ 36.54

Stock-Based Compensation - Stock Option Valuation Assumptions (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	$ 0	$ 0
Granted, weighted-average grant-date fair value (in USD per share)	$ 23.79	$ 20.10
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.20%	30.80%
Expected term in years	6 years	6 years
Risk-free rate	3.60%	2.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.60%	30.90%
Expected term in years	7 years	7 years
Risk-free rate	4.10%	2.90%

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Shares
Outstanding, beginning of period (in shares)	1,081,000	1,100,900
Granted (in shares)	131,100	197,600
Exercised (in shares)	(268,900)	(200,200)
Forfeited (in shares)	(41,000.0)	(10,300)
Expired (in shares)	(2,800)	(800)
Outstanding, end of period (in shares)	899,400	1,087,200
Exercisable, end of period (in shares)	606,200	670,500
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 43.96	$ 40.62
Granted, weighted-average exercise price (in USD per share)	61.81	54.48
Exercised, weighted-average exercise price (in USD per share)	40.23	35.82
Forfeited, weighted-average exercise price (in USD per share)	54.15	49.53
Expired, weighted-average exercise price (in USD per share)	54.47	44.33
Outstanding, end of period, weighted-average exercise price (in USD per share)	47.18	43.94
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 43.23	$ 41.18
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 2 months 12 days	6 years 8 months 12 days
Exercisable, end of period, weighted-average remaining contractual term	5 years	5 years 4 months 24 days
Outstanding, end of period, aggregate intrinsic value	$ 12,703	$ 20,289
Exercisable, end of period, aggregate intrinsic value	$ 10,903	$ 14,360

Income Taxes (Details)	3 Months Ended		9 Months Ended
Income Taxes (Details)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	23.80%	23.70%	23.40%	23.00%

Concentrations of Risk (Details) - manufacturer	3 Months Ended		9 Months Ended
Concentrations of Risk (Details) - manufacturer	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk [Line Items]
Number of third-party manufacturers	129	133	129	133
Sales \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%	19.90%	19.60%	19.80%
Sales \| Customer Concentration Risk \| Amazon
Concentration Risk [Line Items]
Concentration risk, percentage	10.70%		10.40%
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Number of third-party manufacturers with long-term contracts			27	27
Top 5 brands \| Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	37.00%	36.90%	37.80%	38.70%
Manufacturers \| Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			72.10%	70.50%

Business Segments - Information on Operating and Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information, Profit (Loss):
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Cost of sales	124,803	125,122	375,735	370,326
Gross profit	157,938	150,402	472,631	471,530
Advertising and marketing	39,466	30,423	115,799	114,193
Contribution margin	118,472	119,979	356,832	357,337
Other operating expenses	31,640	32,795	96,556	98,755
Operating income	86,832	87,184	260,276	258,582
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	236,565	236,884	727,131	731,456
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	46,176	38,640	121,235	110,400
Operating Segments \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	236,565	236,884	727,131	731,456
Cost of sales	106,090	110,554	323,632	327,008
Gross profit	130,475	126,330	403,499	404,448
Advertising and marketing	33,917	24,831	100,707	99,559
Contribution margin	96,558	101,499	302,792	304,889
Operating Segments \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	46,176	38,640	121,235	110,400
Cost of sales	18,713	14,568	52,103	43,318
Gross profit	27,463	24,072	69,132	67,082
Advertising and marketing	5,549	5,592	15,092	14,634
Contribution margin	21,914	18,480	54,040	52,448
Intersegment Eliminations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 500	$ 1,100	$ 2,500	$ 2,800

Business Segments - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 282,741	$ 275,524	$ 848,366	$ 841,856
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,266	30,044	89,652	91,585
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	33,173	37,582	92,832	96,671
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	58,266	58,056	180,249	188,231
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	61,626	56,749	171,981	168,152
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	45,072	37,882	135,434	123,924
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,768	28,201	98,271	92,436
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,462	24,109	70,991	72,585
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,108	2,901	8,956	8,272
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	236,565	236,884	727,131	731,456
North American OTC Healthcare \| Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,680	29,396	85,838	89,943
North American OTC Healthcare \| Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,359	31,246	73,703	76,896
North American OTC Healthcare \| Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	53,076	53,918	163,031	174,481
North American OTC Healthcare \| Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,919	38,194	122,303	119,533
North American OTC Healthcare \| Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,503	32,653	117,719	109,225
North American OTC Healthcare \| Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,603	27,223	94,299	89,550
North American OTC Healthcare \| Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	20,362	21,371	61,400	63,597
North American OTC Healthcare \| Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,063	2,883	8,838	8,231
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	46,176	38,640	121,235	110,400
International OTC Healthcare \| Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,586	648	3,814	1,642
International OTC Healthcare \| Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,814	6,336	19,129	19,775
International OTC Healthcare \| Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,190	4,138	17,218	13,750
International OTC Healthcare \| Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	22,707	18,555	49,678	48,619
International OTC Healthcare \| Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	6,569	5,229	17,715	14,699
International OTC Healthcare \| Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,165	978	3,972	2,886
International OTC Healthcare \| Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,100	2,738	9,591	8,988
International OTC Healthcare \| Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 45	$ 18	$ 118	$ 41

Prestige Consumer Health... (NYSE:PBH)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Prestige Consumer Health... Charts.

Prestige Consumer Health... (NYSE:PBH)
Historical Stock Chart
From Nov 2023 to Nov 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

PBH Prestige Consumer Healthcare Inc

Latest PBH Messages

Loading Messages....

Prestige Consumer Healthcare Inc News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

PBH Prestige Consumer Healthcare Inc

Latest PBH Messages

Loading Messages....

Prestige Consumer Healthcare Inc News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App